WP01 Protocol: Version 10.0: 24/Jun/2016  Page 1 of 57 
CONTROLLED COPY  
WP01 US Trial Protocol  
A multicenter randomized controlled trial to compare the efficacy of ex-
vivo normothermic machine perfusion with static cold storage in human 
liver transplantation 
  
IDE Ref: G140243  
Protocol Version:  WP01 Version 10.0: (24 June  2016) 
National Principal  
Investigator:  [INVESTIGATOR_346782] , MD 
Professor of Surgery  
Department of Surgery  
Duke University  
[ADDRESS_430811], Durham, NC [ZIP_CODE], [LOCATION_003]  
[EMAIL_6699]   
+[PHONE_7186]  
 
Sponsor /Manufacturer : 
 
US Sponsor:  
 
US Agent:  
 OrganOx Ltd.  
 
NAMSA  
 
NAMSA  
Funder : OrganOx Ltd. 
 
Confidentiality Statement:  This document contains confidential information that must not be disclos ed 
to anyone other than the Spon sor, the US Sponsor , the Investigat ive Team,  
and members of the FDA/IRB  unless authori zed to do so . 
 
Conflicts of Interest:  None  
 
 
 
 
 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 2 of 57 
CONTROLLED COPY STUDY SYNOPSIS  
Trial Title  A multic enter  randomi zed controlled trial to compare the efficacy of ex -vivo 
normothermic machine perfusion with static cold storage in human liver 
transplantation  
Short Title  WP01  – Normothermic liver preservation  
Clinical Phase  Pi[INVESTIGATOR_235068] -label randomi zed controlled trial  
Investigative Sites  Subje cts will be enrolled at up to 15  investigative sites  
Trial Participants  Deceased DBD and DCD liver donor s and adult liver transplant recipi[INVESTIGATOR_346783]  266 transplanted livers (minimum of 120 per arm) , with approximately  [ADDRESS_430812] -transplant procedure.   
Planned trial period  36 months  
 Objectives  Outcome measures/endpoints  
Primary  To compare the effec t of NMP to SCS in 
preventing preservation -related graft 
injury  Severity of immediate graft injury as 
measured by [CONTACT_346857]  
(EAD). 
Secondary  To compare graft and subject  survival 
between NMP and SCS livers.  Primary non -function rates: irreversible 
graft dysfunction requiring emergency 
liver replacement during the first [ADDRESS_430813] -
reperfusion syndrome between NMP 
and SCS livers on transplantation . Assess mean arterial pressure (MAP) 
pre- and post -reperfusion in the context 
of vasopressor use.  
To compare biochemical liver function 
between NMP and SCS livers.  Bilirubin, GGT , ALT, AST, ALP and INR at 
days [ADDRESS_430814] histological criteria.  
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 3 of 57 
CONTROLLED COPY To compare evidence of  biliary 
complications  between NMP and SCS 
livers.  Incidence of biliary investigations and/or 
interventions between [ADDRESS_430815] -transplant.  
To assess the feasibility and safety of 
NMP as a method of organ storage and 
transportation.  Incidence of livers randomized but not 
transplanted and reasons for not -
transplanting.  
To compare organ utili zation between 
NMP and SCS livers.  Incidence of one or more of the 
following  per randomized liver : (i) EAD; 
(ii) discard (non -transplant) of a 
retrieved liver ; (iii) primary non -function .  
To assess the health economic 
implications of normothermic liver 
perfusion.  Logistical and healthcare costs ( length of 
stay in ICU and hospi[INVESTIGATOR_307])  and quality of 
life measures.  
Device name  [CONTACT_346917] ® 
Device 
manufacturer  Organ Ox Ltd, Oxford, [LOCATION_006]  
Length of time 
device has been in 
use Since February 2013  (in two European clinical studies )   
 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430816] (DSMB).  This 
study may be terminated by [CONTACT_1034] /Manufacturer or US Sponsor , with or without cause.  
I agree to personally conduct or supervise this investigation and to ensure that all associates, colleagues, and 
employees assisting in the conduct of this study are informed about their obligations in meeting these 
commitments. 
I will conduct the study in accordance with applicable Good Clinical Practice, and the moral, ethical and 
scientific principles that justify medical research.  The study will be conducted in accordance with all relevant 
laws and regulations relating to clinical studies and the protection of patients.   
I will ensure that the requirements relating to FDA review and approval are met.   
I agree to maintain adequate and accurate records and to make those records available for audit and 
inspection in accordance with relevant regulatory requirements. 
I agree to promptly report to the FDA, the IRB (per their reporting guidelines), and US Sponsor any changes in 
the research activity and all unanticipated problems involving risks to human subjects or others.  Additionally, I 
will not make any changes in the research without regulatory approval, except where necessary to ensure the 
safety of study participants. 
 
 
 
Signature……………………………………………………………………   
 
Name…………………………………………………………………………   
 
Date………………………….  
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430817] (DSMB)  ................................ ................................ ............................ 17 
1.8.2  Clinical Events Committee (CEC)  ................................ ................................................................ ...... 17 
2. Introduction .................................................................................................................................................. 18 
2.1 Background and Rationale  ................................................................ ................................ ...................... 18 
2.1.1 Liver Transplantation – A Successful Therapy  ................................................................ ................. 18 
2.1.2 Liver Failure Epi[INVESTIGATOR_623]  ................................ ................................................................ ............... 18 
2.1.3 The Donor Shortage  ................................................................ ................................ ......................... 18 
2.1.4 Approaches to the Donor Organ Shortage  ................................ ................................ ...................... 18 
[IP_ADDRESS] Living Donation ............................................................................................................................. 19 
[IP_ADDRESS] Higher Risk Donor Organs  ................................ ................................................................ ............. 19 
[IP_ADDRESS] Donation After Circulatory Death (DCD)  ................................ ................................ ....................... 19 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 7 of 57 
CONTROLLED COPY [IP_ADDRESS] Viability Assessment  ................................................................ ................................ ..................... 20 
[IP_ADDRESS] Ex Vivo Reconditioning  ................................ ................................................................ ................. 20 
2.1.5 Cold Storage  ................................ ................................ ................................................................ ..... 20 
2.1.6 Machine Perfusion  ................................................................ ................................ ........................... 21 
2.1.7 Hypothermic Machine Perfusion (HMP)  ................................ ................................ .......................... 21 
2.1.8 Normothermic Machine Perfusion (NMP)  ................................ ................................ ....................... 21 
2.1.9 Preclinical Investigations  ................................ ................................................................ ................. 22 
2.2 Phase 1 Clinical Trial Data ................................................................ ................................ ....................... 23 
3. Objectives ..................................................................................................................................................... 24 
3.1 Hypothesis .............................................................................................................................................. 24 
3.2 Objectives and Outcome Measures/E ndpoints  ................................ ................................ ...................... 24 
3.2.1 Primary Objective  ................................................................ ................................ ............................ 24 
3.2.2 Primary Outcome Measure/ Endpoint  ................................ ................................ ............................. 24 
4. Trial Design  ................................ ................................ ................................................................ ................... 25 
5. Participant Identification  ................................................................ ................................ .............................. 26 
5.1 Study Setting  ................................ ................................ ................................................................ ........... 26 
5.2 Trial Participants  ................................ ................................ ................................................................ ..... 26 
5.2.1 CMS Reimbursement ....................................................................................................................... 26 
5.3 Eligibility Criteria  ................................ ................................ ................................................................ ..... 27 
5.3.1 Donor Criteria  ................................................................ ................................ .................................. 27 
[IP_ADDRESS] Donor Inclusion Criteria ................................................................................................................ 27 
[IP_ADDRESS] Donor Exclusion Criteria ............................................................................................................... 27 
5.3.2 Recipi[INVESTIGATOR_346784]  ................................................................ ................................ ............................. 27 
[IP_ADDRESS] Recipi[INVESTIGATOR_45982] ........................................................................................................... 27 
[IP_ADDRESS] Recipi[INVESTIGATOR_45984] .......................................................................................................... 27 
6. Trial Procedures  ................................ ................................ ................................................................ ............ 27 
6.1 Recruitment ............................................................................................................................................ 27 
6.2 Informed Consent  ................................................................ ................................ ................................... 28 
6.2.1 Recipi[INVESTIGATOR_346785]  ................................................................ ................................ ............................ 28 
6.2.2 Donor Consent  ................................................................ ................................ .................................  28 
6.3 Screening and Eligibility Assessment  ................................ ................................................................ ...... 29 
6.3.1 Recipi[INVESTIGATOR_346786]  ................................................................ ................................ ...................... 29 
6.3.2 Donor Assessment  ................................................................ ................................ ........................... 29 
6.4 Randomization and Blinding  ................................ ................................................................ ................... 29 
6.4.1 Sequence Generation  ................................................................ ................................ ...................... 29 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 8 of 57 
CONTROLLED COPY 6.4.2 Allocation Concealment Mechanism  ................................ ................................ ............................... 29 
6.4.3 Implementation ............................................................................................................................... 29 
6.4.4 Blinding/Masking ............................................................................................................................. 29 
6.5 Pre-Study Baseline Assessments ............................................................................................................ 29 
6.5.1 Donor Demographics  ................................................................ ................................ ....................... 29 
6.5.2 Recipi[INVESTIGATOR_346787]  ................................ ................................................................ .................. 30 
6.5.3 Quality of Life Questionnaire (EQ -5D-5L) ................................ ................................ ........................ 30 
6.6 Trial Interventions ................................................................ ................................ ................................... 30 
6.6.1 NMP Group  (Investigational metra® Device)  ................................................................ ................... 30 
6.6.2 SCS Group  ................................ ................................ ................................................................ ........ 31 
6.6.3 Recording of Operative and Perfusion Parameters  ................................................................ ......... 31 
[IP_ADDRESS] Donor Timings  ................................................................ ................................ ............................... 31 
[IP_ADDRESS].1 DBD Donor Timings .................................................................................................................... 31 
[IP_ADDRESS].2 DCD Donor Timings .................................................................................................................... 31 
[IP_ADDRESS].3 DBD/ DCD Donor Timings  Randomized to NMP  ................................................................ ......... 31 
[IP_ADDRESS] Preservation Parameters for All Randomized Livers .................................................................... 31 
[IP_ADDRESS] Operative Parameters ................................................................................................................... 32 
[IP_ADDRESS] Histological Parameters ................................................................................................................ 32 
6.7 Concomitant Care ................................................................ ................................ ................................... 32 
6.8 Study Visits ................................ ................................ ................................................................ .............. 33 
6.8.1 Inpatient Stay ................................................................ ................................ ................................... 33 
[IP_ADDRESS] Biochemical Assessments ............................................................................................................. 33 
[IP_ADDRESS] Additional Assessments ................................................................................................................ 33 
[IP_ADDRESS] Safety Assessments ....................................................................................................................... 33 
[IP_ADDRESS] Immunosuppression ..................................................................................................................... [ADDRESS_430818] -Transplant Procedure  ................................ ................................ .................................. 33 
[IP_ADDRESS] Biochemical Assessments ............................................................................................................. 34 
[IP_ADDRESS] Additional Assessments ................................................................................................................ 34 
[IP_ADDRESS] Safety Assessments ....................................................................................................................... 34 
[IP_ADDRESS] Immunosuppression ..................................................................................................................... [ADDRESS_430819] -Transplant Procedure  ................................ ................................ ............................... 34 
[IP_ADDRESS] Biochemical Assessments ............................................................................................................. 34 
[IP_ADDRESS] Additional Assessments ................................................................................................................ 35 
[IP_ADDRESS] Safety Assessments ....................................................................................................................... 35 
[IP_ADDRESS] Immunosuppression ..................................................................................................................... 35 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430820] -Transplant Procedure  ................................ ................................ ............................... 35 
[IP_ADDRESS] Biochemical Assessments ............................................................................................................. 35 
[IP_ADDRESS] Additional Assessments ................................................................................................................ 35 
[IP_ADDRESS] Safety Assessments ....................................................................................................................... 36 
[IP_ADDRESS] Immunosuppression ..................................................................................................................... [ADDRESS_430821] -Transplant Procedure  ................................ ................................ ............................. 36 
6.9 Participant Retention  ................................................................ ................................ .............................. 36 
6.10 Definition of the End of the Trial ................................ ................................................................ .......... 36 
7. The OrganOx metra ® Device  ................................................................ ................................ ......................... 37 
7.1 Device Description  ................................................................ ................................ .................................. 37 
7.1.1 The OrganOx metra® Base Unit  ................................ ................................................................ ....... [ADDRESS_430822] ......................................................................................................... 39 
8.1.2 Interim Analyses  ................................................................ ................................ .............................. 39 
8.2 Adverse Events  ................................ ................................ ................................................................ ....... 39 
8.2.1 Definitions ........................................................................................................................................ 39 
8.2.2 Adverse Event Severity Definitions .................................................................................................. 40 
8.2.3  Anticipated Adverse Events  ................................ ................................................................ ............. 40 
8.2.4 Device Deficiency  ................................................................ ................................ ............................. 40 
[IP_ADDRESS]  Device Failures  ................................................................ ................................ .......................... 41 
[IP_ADDRESS]  Device Malfunctions  ................................ ................................................................ ................. 41 
[IP_ADDRESS]  Use Errors  ................................................................ ................................ .................................  41 
8.2.5 Procedures for Recording Adverse Events  ................................ ................................ ....................... 41 
8.2.6  Reporting Procedures for All Adverse Events  ................................................................ .................. 41 
8.3 Study Suspension or Early Termination  ................................ ................................ .................................. 42 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 10 of 57 
CONTROLLED COPY 9. Statistics ........................................................................................................................................................ 42 
9.1 Description of  Statistical Methods  ................................ ................................................................ ......... 42 
9.1.1 General Statistical Considerations ................................................................................................... 42 
9.1.2 Conditional Phase Analyses ............................................................................................................. 43 
9.1.3 S tudy  Cohorts  for Analyses  ................................ ................................................................ .............. 43 
9.1.4 Primary Outcome ............................................................................................................................. 43 
9.1.5 Secondary Outcomes ....................................................................................................................... 44 
9.1.6 Safety Analyses ................................................................................................................................ 44 
9.1.7 Subgroup Analyses ........................................................................................................................... 44 
9.1.8 Poolability Analysis  ................................................................ ................................ .......................... 44 
9.1.9  Missing Data  ................................ ................................ ................................................................ .... 45 
9.2 Sample Size ................................ ................................ ................................................................ ............. 45 
9.3 Additional Analyses and Deviation from the Statistical Analysis Plan ................................ .................... 45 
10. Data Collection and Management  ................................ ................................................................ .............. 45 
10.1 Data Collection Methods  ................................................................ ................................ ...................... 45 
10.1.1 Source Data ................................ ................................ ................................................................ .... 45 
10.1.2 Data Recording  ................................................................ ................................ .............................. 46 
10.2 Data Management  ................................................................ ................................ ................................ 46 
10.2.1 Data Forms and Data Entry ................................ ................................................................ ............ 46 
10.2.2 Discrepancies and Missing Data ................................ ................................................................ .... 46 
10.2.3 Security and Backup of Data ................................ ................................................................ .......... 46 
10.2.4 Data Access  ................................ ................................ ................................................................ .... 46 
10.2.5 Data Retention  ................................................................ ................................ ............................... 46 
11. Quality Assurance, Audit and Training ................................ ................................................................ ........ 46 
11.1 Monitoring ............................................................................................................................................ 46 
11.2 Quality Assurance Auditing and Inspection .......................................................................................... 47 
11.3 Local Investigator and Site Personnel Training  ................................ ................................ ..................... 47 
11.4 Study Documentation  ................................................................ ................................ ........................... 47 
12. Protocol Deviations  ................................ ................................ ................................................................ ..... 47 
12.1 Definitions ............................................................................................................................................. 47 
12.2 Reporting of Protocol Deviations  ................................ ................................................................ .......... 48 
13. Ethical and Regulatory Considerations  ................................ ................................................................ ....... 48 
13.1 IRB and FDA Approval  ................................................................ ................................ ........................... 48 
13.2 Protocol Amendments  ................................................................ ................................ .......................... 48 
13.3 Reporting  ................................ ................................ ................................................................ .......... 48 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 11 of 57 
CONTROLLED COPY 13.3.1 Sponsor Reports ................................................................ ................................ ............................. 48 
13.3.2 Investigator Reports  ................................................................ ................................ ...................... 49 
13.4 Participant Confidentiality  ................................................................ ................................ .................... 50 
13.5 Expenses and Benefits  ................................................................ ................................ .......................... 50 
14. Dissemination Policy  ................................................................ ................................ ................................... 51 
14.1 Data Analysis and Release of Results  ................................ ................................................................ .... 51 
14.2 Primary Outcome Publications ................................ ................................................................ ............. 51 
Appendix A 1: Timeline for Interventions and Assessments Durin g the Study  ................................ ............. 52 
Appendix A 2: Protocol Amendments  ................................ ................................................................ ........... 54 
References ........................................................................................................................................................ 55 
  
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430823]  Aspartate Transaminase 
ATP  Adenosine Triphosphate 
BMI  Body Mass Index 
CEC  Clinical Events Committee 
CFR  Code of Federal Regulations 
CIT  Cold Ischemia Time 
CMS  Centers for Medicare & Medicaid Services 
CRF  Case Report Form 
CVA  Cerebrovascular Accident 
DBD  Donation after Brain Death 
DCD  Donation after Circulatory Death 
DPMP  Donors per Million Population per Year 
DRI  Donor Risk Index 
DSMB   Data Safety Monitoring Board 
EAD  Early Allograft Dysfunction 
ECD  Extended Criteria Donor 
eCRF  Electronic Case Report Form 
EDC  Electronic Data Capture 
ERCP  Endoscopic Retrograde Cholangiopancreatography 
FDA  Food & Drug Administration 
GCP  Good Clinical Practice 
GGT  Gamma-Glutamyl Transferase 
GST  Glutathione S -Transferase  
H0  Null Hypothesis 
HA  Alternative Hypothesis 
HCC  Hepatocellular Carcinoma 
HCV  Hepatitis C Virus 
HD  Hemodialysis 
HDF  Hemodiafiltration 
HF  Hemofiltration 
HMP  Hypothermic Machine Perfusion 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430824] 
UNOS  United Network for Organ Sharing 
UW  University of Wisconsin Preservation Solution  
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 14 of 57 
CONTROLLED COPY 1. ADMINISTRATIVE INFORMATION  
1.1 TI TLE  
“A multicenter randomized controlled trial to compare the efficacy of ex-vivo normothermic machine 
perfusion with static cold storage in human liver transplantation. ” 
1.2 TR IAL REGISTRATION  
This trial protocol is registered with clinicaltrials.gov in accordance with regulations.  The national clinical trial 
identifier is [STUDY_ID_REMOVED]. 
1.3  PROTOCOL VERSION  
1.3.1  CURRENT VERSION  
Version number: WP01 Version 10.0  
Issue date : [ADDRESS_430825] UDY FUNDING  
OrganOx Ltd 
1.5 SP ONSOR  
The trial is sponsored by [CONTACT_346858]. 
The US Sponsor and US Agent is NAMSA.  
The Sponsor/Manufacturer will approve this protocol prior to study commencement. 
1.6 TRIAL PERSONNEL  
1.6.1  NATIONAL PRINCIPAL  INVESTIGATOR  
[INVESTIGATOR_346788] : 
Stuart Knechtle MD ; Duke University   
1.6. [ADDRESS_430826]  
Histopathology  will be carried out  by a central laboratory in accordance with a study laboratory 
manual.  
   
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 15 of 57 
CONTROLLED COPY 1.7  RO LES AND RESPONSIBILITIES  
1.7.1  SPONSOR RESPONSIBILITIES   
 General responsibilities (§812.40)  
Sponsors are responsible for selecting qualified investigators and providing them with the 
information that they need to conduct the investigation properly. They must also ensure proper 
monitoring of the investigation and IRB review and approval, submit an IDE application to FDA for 
significant risk device studies, and inform the IRB and FDA promptly of any significant new 
information about the investigation. 
 FDA and IRB approval (§812.42)  
A sponsor cannot begin an investigation or any part of an investigation until an IRB and FDA have 
both approved the application or supplemental application. 
 Selecting Investigators (§812.43)  
A sponsor is responsible for selecting investigators qualified by [CONTACT_346859]. 
 Selecting Monitors (§812.43)  
A sponsor must select monitors qualified by [CONTACT_346860]. 
 Device Control (§812.43)  
A sponsor can ship investigational devices only  to qualified investigators participating in the 
investigation. 
 Investigator Agreements (§812.43)  
A sponsor must obtain a signed agreement from each participating investigator that includes: 
o The investigator's curriculum vitae,  
o A statement of the investigator's relevant experience, including the dates, location, extent, 
and type of experience, where applicable,  
o An explanation of the circumstances that led to termination of a study if the investigator 
was involved in an investigation or other research that was terminated,  
o A statement of the investigator's commitment to:  
 Conduct the investigation in accordance with the agreement, the investigational 
plan, the IDE and other  applicable FDA regulations, and conditions of approval 
imposed by [CONTACT_115482],  
 Supervise all testing of the device involving human subjects  
 Ensure that the requirements for obtaining informed consent are met. 
 Sufficient accurate financial disclosure information to allow a sponsor to submit a 
complete and accurate certification or disclosure statement as required under 21 
CFR 54, Financial Disclosure by [CONTACT_6230]. A sponsor shall also obtain a 
commitment from the clinical investigator to promptly update this information if 
any relevant changes occur during the course of the investigation and for one year 
following completion of the study.  
 Informing Investigators (§812.4 5)  
A sponsor must supply all investigators participating in the investigation with copi[INVESTIGATOR_346789] a report of prior investigations of the device. 
 Monitoring (§812.46) 
Securing Compliance : A sponsor who discovers that an investigator is not complying with the signed 
agreement, the investigational plan, the IDE requirements, any other applicable FDA regulations, or 
any conditions of approval imposed by [CONTACT_346861], or discontinue shipments of the device to the investigator and terminate the 
investigator's participation in the investigation. A sponsor must also require that the investigator 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430827].  
Unanticipated Adverse Device Effects : A sponsor must immediately conduct an evaluation of any 
unanticipated adverse device effect. A sponsor who determines that an unanticipated adverse device 
effect presents an unreasonable risk to subjects must terminate all investigations or parts of the 
investigations presenting that risk as soon as possible. Termination must occur no later than [ADDRESS_430828].  
Resumption of Terminated Studies : a sponsor may not resume a terminated investigation without IRB 
and FDA approval. A sponsor may not resume a terminated investigation without IRB approval.  
 Sponsor records (§812.140)  
A sponsor must maintain accurate and complete records relating to the investigation. These records 
include: 
o All correspondence including required reports,  
o Records of shipment of the device,  
o Records of disposition of the device,  
o Signed investigator agreements including financial disclosure information,  
o Records concerning complaints and adverse device effects whether anticipated or not,  
o Any other records that FDA requires to be maintained by [CONTACT_3902] a category of investigation or a particular investigation. 
 Sponsor Reports (§812.150)  
A sponsor must provide the following reports in a timely manner to FDA, the IRB's, and/or the 
investigators. 
o Unanticipated Adverse Device Effects  
o Withdrawal of IRB Approval  
o Withdrawal of FDA Approval  
o Current List of Investigators  
o Progress Reports  
o Recalls and Device Disposition  
o Final Report  
o Use of device without Informed Consent  
o Significant Risk Device Determination  
1.7.2  INVESTIGATOR RESPONSIBILITIES   
 The investigator is responsible for protecting the rights, safety, and welfare of subjects. An 
investigator must conduct the investigation in accordance with the signed agreement with the 
sponsor, the investigational plan, the IDE regulations and other applicable FDA regulations, and any 
conditions of approval imposed by [CONTACT_346862]. (§812.100) 
 While awaiting approval, an investigator may determine whether or not potential subjects would be 
interested in participating in an investigation, but cannot request written informed consent or allow 
any subjects to participate before obtaining IRB and FDA approval.  (§812.110) 
 An investigator is responsible for obtaining informed consent under 21 CFR Part 50. 
 Supervision of device use : An investigator can permit use of the investigational device only with 
subjects under his/her supervision and must not supply an investigational device to any person not 
authorized under the regulations to receive it.   (§812.110)  
 Financial Disclosure (§812.110) 
The clinical investigator must disclose to the sponsor sufficient accurate financial information to allow 
the IDE applicant (or sponsor) to submit certification or disclosure of financial interests under 21 CFR 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430829] update the information if any relevant changes occur during the course of 
the investigation and for one year following completion of the study. 
 Device Disposal (§812.110) 
Upon completion or termination of a clinical investigation or the investigator's part of the 
investigation or at the sponsor's request, an investigator must return to the sponsor any remaining 
supply of the device or dispose of the device as the sponsor directs. 
 Records (§ 812.140)  
The investigator must maintain accurate and complete records relating to the investigation. These 
records include: 
o All correspondence including required reports, 
o Records of receipt, use, or disposition of the investigational device, 
o Records of each subject's case history and exposure to the device, 
o The protocol and documentation (date and reason) for each deviation from the protocol, 
o Any other records that FDA requires to be maintained by [CONTACT_3902] a category of investigation or a particular investigation. 
 Investigator Reports (§ 812.150)  
The investigator must provide the following reports in a timely manner to the sponsor and/or the IRB: 
o Unanticipated Adverse Device Effects 
o Withdrawal of IRB Approval 
o Progress Reports 
o Deviations from the Investigational Plan 
o Failure to obtain Informed Consent 
o Final Report 
 The Investigators  will be responsible for: 
o Identification and recruitment of patients to the study 
o Conducting clinical procedures in accordance with the protocol and standard operating 
procedures 
o Data collection and completion of electronic CRFs 
o Follow-up of study participants 
1.[ADDRESS_430830] (DSMB ) 
The DSMB will be appointed to monitor the conduct of the study and subject safety by [CONTACT_346863]. The DSMB will oversee the overall safety of the current and future study subjects by 
[CONTACT_346864]. The DSMB will review adverse events and other relevant study data and 
will make recommendations regarding continuation of the study to the US Sponsor.  
1.8. 2 CLINICAL EVENTS COMMITTEE (CEC)  
The CEC is composed of transplant surgeons or other clinicians with relevant expertise who are not 
participating in this study, and who do not have significant investment with the study Sponsor/Manufacturer 
or US Sponsor.  The CEC is charged with the review and classification of adverse events (AEs), including deaths.  
The CEC will establish rules outlining the minimum data required and the algorithm followed in order to 
classify AEs.  All members of the CEC will meet regularly to review and classify AEs.  All appropriate data will be 
reviewed by [CONTACT_15741]. The CEC will forward a report of event review and classifications as outlined in the CEC 
charter.   
 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 18 of 57 
CONTROLLED COPY 2. INTRODUCTION  
2.1 BA CKGROUND AND RATIONALE  
2.1.1  LIVER TRANSPLANTATION – A SUCCESSFUL THERAPY  
Liver transplantation is the only effective treatment for many patients with liver disease. For patients with liver 
failure, techniques for supporting liver function provide only limited and temporary benefit as a bridge to 
transplantation or liver regeneration in the case of acute liver failure. In contrast to kidney dialysis support i n 
renal failure, there is no artificial means to support a patient with liver failure for an extended period. Since 
the first clinical case in 1963, transplantation of the liver has developed to an established and standardized 
procedure as cure for acute and chronic liver disease. The results of liver transplantation have greatly 
improved and patient survival rates of over 90% at one year and 70% at five years are routinely achieved for 
elective liver transplantation. As a result, liver transplantation has become the mainstay of treatment for an 
increasing spectrum of patients with chronic liver disease, metabolic liver disease, acute liver failure and some 
liver cancers.   
2.1.[ADDRESS_430831] common indication for liver transplantation ( 42%), other indications include 
cancer ( 22%), and acute hepatic necrosis (4%) [www.srtr.org – 2012 annual report]. The main causes for 
cirrhosis in the US are virus related cirrhosis and alcoholic liver disease . It is predicted that HCV-related 
hepatocellular carcinoma (HCC) will continue to increase during the next decade, despi[INVESTIGATOR_346790]. Meanwhile, the incidence of liver disease related to both obesity a nd 
alcohol consumption is expected to increase despi[INVESTIGATOR_346791]. It is very likely that the demand for 
donor livers suitable for transplantation will continue to rise, exacerbating the existing organ shortage. 
2.1.[ADDRESS_430832] two decades, liver transplantation has become a victim of its own success: many more patients 
are referred for transplantation, but the number of suitable grafts from deceased organ donors has increased 
more slowly. The donor organ shortage constitutes a serious risk for patients with liver failure. It is the 
principal cause of increasing waiting lists and the death of patients on the waiting list worldwide. In 2012, 
6,[ADDRESS_430833], 
and there was a mortality rate of 19% on the waiting list.  This shortfall is typi[INVESTIGATOR_346792]. In many countries, a patient is now more likely to die on the waiting list for a 
transplant than in the [ADDRESS_430834] been made in recent years to increase the referral of organ donors, but an increasing 
proportion of deceased donors are suboptimal. These include donors declared dead by [CONTACT_346865] 
(‘donation after circulatory death’, DCD) and other ‘extended criteria’ organ donors (older age, steatosis , etc.). 
There has been a much smaller increase in the number of standard criteria (‘ideal’) organ donors, including 
younger donors declared dead by [CONTACT_346866] (‘donation after brain death’, DBD). This is reflected in 
the utilization of donor organs – in 2012, 74% of solid organ donors in the [LOCATION_003] resulted in a liver transplant 
(OPTN data). 
2.1.4  APPROACH ES TO THE DONOR ORGAN SHORTAGE  
Organ donor rates in other countries range widely: using [ADDRESS_430835] rate occurred in Spain with 
35.3 donors per million population per year (DPMP), compared to the [LOCATION_006] (17 DPMP)  and the [LOCATION_003] (25 DPMP) . 
It is generally accepted that these discrepancies are due  not only to cultural distinctions but also due to 
political and legal differences. There is debate as to whether the situation is simpler in those countries that 
practice “presumed consent” (opting out) [1]. Most countries, however, practice a system of “ opting in,” 
whereby [CONTACT_346867].  
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 19 of 57 
CONTROLLED COPY Due to the critical shortage of donor organs, clinicians are continually searching for ways to overcome the 
discrepancy between demand and availability of donor livers for transplantation. Additional sources of organs 
include those from living donors, organs from DCD (donation after circulatory death) donors (previously known 
as ‘non -heart- beating donors’) and other less -than- optimal (‘higher risk’) deceased donors.  
[IP_ADDRESS]  LIVING DONATION   
Living donation is one potential means to increase the number of liver transplants, using surgical techniques 
developed for ´liver splitting´ (a technique for using a single liver for transplantation into two recipi[INVESTIGATOR_840]). The 
major limitations of this technique include, first, the fact that most patients do not have a willing and suitable 
living donor, and, second, real concerns about the risks to the healthy donor. The reported risk of donor death 
is estimated at 0.2% but the risk of serious complications is much higher [2]. For these and other reasons living 
donor transplantation has had limited impact on the shortage of donor livers for transplantation in most 
countries (only 246 such transplants were performed in the [LOCATION_003] in 2012) . 
[IP_ADDRESS]  HIGHER  RISK DONOR ORGANS  
Much emphasis is now placed on optimi zing the condition of those organs that are available, to enable an 
increased number of higher risk organs to be transplanted safely. The use of a higher risk organ does 
constitute a greater risk to t he recipi[INVESTIGATOR_841], with a higher probability that the organ will never function and 
require immediate replacement (primary non -function ; PNF), that it will function poorly and place the patient 
at risk of other complications (early allograft dysfunction; EAD) o r that it will lead to later complications 
including multiple stricturing of the biliary tree (ischemic cholangiopathy; IC).  
The serious effects of the organ shortage, with many patients dying on the waiting list, has led to increased 
interest in using donor livers which were formerly thought unsuitable for transplantation. The use of these 
´extended criteria donors´ (ECD; also called ‘marginal’ or ‘high risk’) donor livers for liver transplantation is now 
seen as essential if liver transplant units are to address the demand. Several donor parameters have been 
identified as relative risk factors for poor outcome, including age; steatosis; DCD donation; split livers; 
prolonged cold ischemia time (>12 hours). These were all developed using North American data and 
formulated into an algorithm known as the ‘Donor Risk Index’ (DRI) [3], and later validated using European 
data [4]. 
[IP_ADDRESS]  DONATION AFTER CIRCULATORY DEATH (DCD)  
For many years (following the establishment of brain death criteria) in most countries, deceased donor organs 
were almost exclusively sourced from donors declared dead by [CONTACT_346868] (donation after brain 
death, DBD). In such cases the donor remains on ventilatory support and cardiopulmonary function is 
maintained until the donor has been transferred to the operating room, preliminary dissection has been 
performed, cannulae placed and the organs are ready for cooling. This enables organs to be removed with 
minimal interruption to oxygenation before cooling and preservation. In contrast, in the case of DCD donors, 
death is certified after cardiac arrest using cardiovascular parameters; this causes an inevitable period of 
oxygen deprivation between cardiac arrest and cold preservation of the organs. DCD donors have been 
classified as ‘uncontrolled’, in which death is not predicted (typi[INVESTIGATOR_346793]) and ‘controlled’ in which death is anticipated (typi[INVESTIGATOR_346794] -support is 
withdrawn from a patient in whom continued treatment has been deemed to be futile). 
In the latter situation, because death is anticipated and the transplant team can be mobili zed in advance, the 
period of ‘warm ischemia’ sustained by [CONTACT_346869]; livers from this source have 
been transplanted in substantial numbers in recent years, although very selectively, but with higher rates of 
primary non -function and other post -operative complications than DBD livers, with worse long -term graft 
survival [5 -7].  This increase in complicat ions results in an increased cost incurred with DCD transplantation [8]. 
In contrast, livers from uncontrolled DCD are not generally used for transplantation because of a high rate of 
primary non -function in the experience of those centers that have attemp ted this [9]. It has been estimated, 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 20 of 57 
CONTROLLED COPY however, that effective use of these potential donors would add greatly to the number of organ donors [10]. 
This contrasts with the situation in renal transplantation in which organs from uncontrolled DCD have been 
used by [CONTACT_346870] [11]. 
Following renal transplantation, a period of ‘delayed graft function’ is acceptable because it is possible to 
support the patient with dialysis whilst the transplanted organ recovers from the ischemic injury; an 
equivalent delay in initial function of a transplanted liver is fatal without urgent re-transplantation. 
[IP_ADDRESS]  VIABILITY ASSESSMENT  
The safety and utility of DCD liver transplantation would be greatly improved by a reliable test to quantify the 
ischemic/preservation injury and assess viability in order to predict the outcome after transplantation. Even 
after careful pre-retrieval donor selection, up to 45% of retrieved livers from DCD donors are discarded due to 
doubts about viability [12]. In the U S in 20 13  6,449  of 7,137  (90%) of all deceased donor livers retrieved were 
actually transplanted, falling to 360 of 492 (73%) for livers from DCD donors ( SRTR data ). In addition to these 
losses, many DCD donor or gans are declined without being retrieved because of concerns about risk factors.  
An effective means of pre -transplant viability assessment would not only allow greater use of higher risk 
donors but also minimi ze the risk of primary non -function by [CONTACT_346871] -viable organs 
before subjecting a patient to the risk of surgery.  
[IP_ADDRESS]  EX VIVO RECONDITIONING  
A further strategy in the quest to use higher risk donor organs successfully is that of ‘reconditioning’ after 
retrieval – using techniques to reverse the injury sustained by [CONTACT_346872] a way as to minimi ze the immediate damage that occurs after 
transplantation (ischemia -reperfusion injury). Treatment of the or gan during preservation has major logistic 
and ethical advantages over any attempt to achieve the same effects by [CONTACT_346873] (in many countries 
therapeutic interventions before declaration of death that are of no potential benefit to the donor are not 
permitted).  Many cytoprotective strategies have been tested in experimental models of transplantation and 
several have been shown to have therapeutic potential, including various antioxidants, inflammation 
inhibitors, vasodilating agents, inhibitors o f chemotaxis or neutrophil infiltration.  
At the moment the flow of oxygenated blood ceases, the supply of oxygen, cofactors, and nutrients stops 
along with the means of disposal of metabolic waste products. Anaerobic metabolism continues (at a 
temperature-dependent rate), leading to depletion of energy stores, mainly adenosine tri-phosphate (ATP), 
with a concomitant build-up of an acidotic milieu. ATP is required for energy-dependent cellular functions, 
including the integrity of sodium/potassium pumps that maintain electrolyte balance across cell membranes 
and ATP depletion leads to loss of trans-cellular electrolyte gradients, cell swelling, influx of free calcium, and 
the subsequent activation of phospholipases. The breakdown of ATP during ischemia also generates substrates 
for the production of reactive oxygen intermediates on reperfusion and initiates the cascade of ischemic 
injury. Prevention of ATP depletion is therefore an important target of innovative preservation methods. It has 
been shown that providing an oxygen supply to the organ can prevent ATP depletion and preserve viability 
following cardiac arrest in a porcine liver transplant model [13].  
2.1.5  COLD STORAGE  
Organs retrieved for transplantation undergo injury at several consecutive stages: 1) warm ischemia prior to 
preservation, 2) cold preservation injury, 3) ischemic rewarming during surgical implantation and 4) 
reperfusion injury. These consecutive events lead to a cumulative cellular injury that may not be compatible 
with recovery after transplantation.  
Standard clinical practice involves flushing and cooling the liver in situ with preservation solution; University of 
Wisconsin [UW] solution is used most commonly although Histidine-Tryptophane-Ketoglutarate [HTK] solution 
is also widely used. Typi[INVESTIGATOR_346795]. Additional cooling may be provided by 
[CONTACT_346874]01 Protocol: Version 10.0: 24/Jun/2016  Page 21 of 57 
CONTROLLED COPY topi[INVESTIGATOR_346796]. After retrieval, the organ is placed in sterile plastic bags for 
transportation and stored in an ice-box in preservation solution until transplantation.  Although the available 
preservation solutions differ in chemical composition, the function is essentially the same: to prevent cellular 
swelling and death caused by [CONTACT_346875]-exchange pumps cease operating in the cold 
environment. Although cold preservation slows metabolism by 1.5- to 2-fold for every 10°C drop in 
temperature, considerable metabolic activity still occurs at 1°C. This leads to accumulation of metabolic 
products which act as substrates for metabolism that takes place when the organ is re-perfused with 
oxygenated blood – the basis of the ischemia-reperfusion phenomenon [14] 
In organs retrieved from DCD donors the deleterious effects of cold ischemia are superimposed on the injury 
sustained during warm ischemia, which causes rapid depletion of ATP. There are some differences in the 
pattern of injury sustained during warm and cold ischemia; the latter causes initial injury to sinusoidal 
endothelial cells whereas warm ischemia is more damaging to hepatocytes and cholangiocytes.  
Cold storage causes injury to the graft regardless of other factors. It has been known for many years that 
extended preservation time with cold preservation solution has a deleterious effect on organ viability [15, 16] 
with a clear correlation between cold-ischemia time and post-operative primary graft function. The rate of 
primary non-function was reported in a large registry analysis as 5.8% [17], although individual center reports 
show a range of incidence. Although a strong correlation has been shown between preservation injury and 
subsequent acute rejection [18], this has not been confirmed in other reports [19]. Preservation injury is a 
more critical issue in higher risk donor organs - whereas good quality livers can tolerate preservation periods 
even up to [ADDRESS_430836] half of the twentieth century, for example, Carrel perfused organs with normothermic, 
oxygenated serum and demonstrated gross viability for several days [20]. A number of early successful clinical 
liver transplants carried out by [INVESTIGATOR_124] . Thomas Starzl, used machine perfusion with diluted blo od under cold 
hyperbaric conditions [21]. This technique never gained popularity, partly due to its complexity and logistic 
challenges but also the subsequent introduction of effective cold flush preservation solutions.  Subsequent 
research into extracorpo real machine perfusion largely centered on liver support [22].  
2.1.7  HYPOTHERMIC MACHINE PERFUSION (HMP)  
It has been demonstrated experimentally by [CONTACT_346876], in terms of immediate graft function 
and medium-term outcome of deceased kidneys and DCD organs specifically [23, 24]. The mechanism of 
benefit is not fully understood, but probably relates both to the removal of metabolic products as well as the 
delivery of oxygen (although in the absence of formal oxygenation or specialist oxygen carrier molecules, 
oxygen delivery is likely to be limited).  
HMP offers the additional benefit of some (limited) assessment of pre-transplant organ viability by 
[CONTACT_346877] αGST levels and other biomarkers as a marker of 
cellular injury. It also provides the potential for local therapeutic intervention. Several groups have claimed 
advantages with hypothermic machine perfusions in liver transplantation and the first human clinical study of 
ex-vivo liver HMP has been published [25, 26]. 
2.1.8  NORMOTHERMIC MACHINE PERFUSION  (NMP)  
There is accumulating evidence of the superiority of a more physiological approach using oxygenated blood at 
normal body temperature. Several studies demonstrate that the quality of preservation can be improved 
substantially by [CONTACT_346878], by [CONTACT_346879] a supply of 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 22 of 57 
CONTROLLED COPY oxygen and nutrition [27, 28]. These data are mainly based on organ retrieval, preservation, ex-situ-evaluation 
and transplantation in large animal models (pi[INVESTIGATOR_14107]). In the experimental setting normothermic perfusion has 
been shown to resuscitate porcine livers subjected to 60 to 90 minutes of warm ischemia [14, 29]. Warm 
perfusion has the added advantage of allowing more effective viability assessment of the organs while on the 
circuit (using multiple perfusion dynamic and biochemical parameters), contrasting with the more limite d 
parameters available on the hypothermic circuit [27]. Preclinical liver transplant experiments in the pig model 
from a number of centers [27, 28, 30] have shown that the normothermically preserved liver can be 
transplanted reliably and successfully after warm ischemic injuries that do not allow survival using cold 
preservation. If these results were translated into clinical practice, this would generate a large new source of 
donor organs. 
Normothermic perfusion has been shown as feasible in the setting of human renal transplantation [31], with a 
potential benefit of a reduction in the rate of delayed graft function in organs retrieved from extended criteria 
donors [32]. 
2.1.9  PRECLINICAL INVESTIGATIONS  
The experimental precursor to the proposed normothermic perfusion system was developed more than 15 
years ago and the method of perfusion of the isolated pig liver with autologous blood has since been 
extensively tested and refined, although the overall design of the perfusion circuit remains unchanged [ 33]. 
The circuit incorporates a centrifugal pump, membrane oxygenator, and heat exchanger. Arterial perfusion is 
directly pumped and the portal vein is perfused via a soft-shell reservoir using gravitational force. The addition 
of various substrates to the perfusion solution enables maintenance of metabolic function [ 34, 35]. 
The initial preservation experiments were carried out to compare preservation by [CONTACT_346880] [ 29]. Porcine livers were retrieved and stored for a period of 24 hours, either 
flushed with UW solution and placed in an icebox or attached immediately to the preservation circuit. Both 
groups of livers were then reperfused on the circuit for 24 hours (as a surrogate for transplantation) and 
markers of cellular injury and of synthetic and metabolic liver function were measured. These experiments 
demonstrated significant superiority of normothermic machine perfusion in terms of hemodynamic, 
biochemical and histological parameters.  
Subsequent experiments investigated the use of oxygenated, normothermic perfusion in an experimental 
setting that reflected the clinical situation of DCD donor organ retrieval [ 14]. Perfusion with normothermic 
blood was again compared with static cold storage after [ADDRESS_430837], cold stored livers showed no evidence of viability during reperfusion and massive necrosis on 
histological examination. 
It is recognized that the combination of warm ischemia and conventional cold preservation leads to a poor 
outcome in DCD liver transplantation [ 7]. In the experimental setting, it is possible to institute warm perfusion 
with minimal exposure of the organ to cooling. However, in contrast, the logistics of clinical multi-organ 
retrieval in a distant donor hospi[INVESTIGATOR_346797] a period of cold preservation prior 
to normothermic preservation. This would enable the liver to be retrieved in the normal way, transported in 
an ice box and then attached to the perfusion machine once back at the base hospi[INVESTIGATOR_307]. This scenario was 
simulated in the same experimental model by [CONTACT_4859] a period of cold preservation prior to normothermic 
preservation [ 36]. Porcine livers were subjected to 60 minutes of warm ischemia and then assigned to either 
normothermic preservation for 24 hours or cold preservation in University of Wisconsin solution for 4 hours 
followed by 20 hours normothermic preservation to achieve a total preservation time of 24 hours [ 36]. Livers 
that underwent normothermic preservation throughout had superior bile production, metabolic activity (base 
deficit and greater glucose use), and less hepatocellular damage (transaminase levels), and sinusoidal 
endothelial cell dysfunction (hyaluronic acid). The histology of livers that had been exposed to 4 hours of cold 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 23 of 57 
CONTROLLED COPY preservation before normothermia showed more necrosis and destruction of architecture. A similar study 
investigated 60 minutes of warm ischemia followed by 60 minutes of cold preservation before 23 hours of 
normothermic perfusion [ 37]. This also showed evidence of increased hepatocellular injury, sinusoidal cell 
injury, but no detriment in terms of protein synthesis (factor V), bile production or histological features. These 
studies, therefore, demonstrated the need for the warm preservation device to be transportable so that 
normothermic preservation can be instituted with a minimal period of cooling at the time of organ retrieval.  
In order to confirm these results in a preclinical model of organ transplantation, a series of liver transplants in 
a pig model was performed [ 27]. In these experiments pig livers were cold-preserved or warm-preserved 
(using the same machine perfusion methodology as before) for either 5 hours or 20 hours, followed by [CONTACT_346881]. As a model of DBD and DCD clinical scenarios, organs were cold-perfused in situ  either at the 
time of cessation of circulation (as in a DBD organ donation) or after 40 and 60 minutes of warm ischemia 
(simulating DCD organ donation). The two preservation times were selected because 5 hours is comfortably 
within, and 20 hours substantially beyond, the limit of the conventional cold preservation technology in pi[INVESTIGATOR_14107] 
(in which a generally accepted limit for survival is 12 hours). Similarly the [ADDRESS_430838] of transplantation 
of donor livers from uncontrolled DCD donors. 
There was no difference in outcome between the two groups at 5 hours of preservation. After 20 hours of 
preservation, there were significant advantages consistently in warm compared to cold preservation of both 
DBD and DCD organs. These advantages applied to postoperative enzyme release and animal survival. Notably, 
in the 20 hour warm-preserved groups, there was no difference in survival or postoperative transaminase 
levels in recipi[INVESTIGATOR_346798] (40 minute warm ischemia) donor organs (86% versus 83%). At 60 
minutes of warm ischemia and 20 hours normothermic preservation, however, there were no survivors. 
Analysis of hemodynamic, synthetic and metabolic parameters showed that those groups of livers that 
subsequently went on to successful transplant were predictable before transplantation on the basis of portal 
flow/pressure, acid-base homeostasis and several other biochemical parameters [ 27]. It may be concluded 
that normothermic perfusion, in this context, is not only a more effective means of organ preservation than 
conventional cold storage, but also that this method can be configured to provide an effective means of 
viability assessment [ 38]. 
The prototype version of the automated clinical investigation device has been tested and demonstrated to be 
effective during pre-clinical studies in which human livers, discarded as unsuitable for transplantation, were 
perfused for [ADDRESS_430839] been shown to be equally applicable to human as to pig livers (manuscript in 
preparation). More recently, the clinical trials device has been tested, using livers declined for clinical 
transplantation, and all key functional aspects of the device shown to be operational, including particularly 
transport to the donor hospi[INVESTIGATOR_307], automation and 24 hour perfusion. 
2.2  PH ASE 1 CLINICAL TRIAL DATA 
A pi[INVESTIGATOR_346799]’s College Hospi[INVESTIGATOR_35905] 2012 and  extended to the Queen Elizabeth 
Hospi[INVESTIGATOR_307], Birmingham in 2013. Between February and December 2013, 20 subjects underwent liver 
transplantation using donor organs preserved throughout by [CONTACT_346882]. Sixteen livers (80%) 
were from DBD and 4 (20%) were from DCD (Maastricht category III) donors. The indication for transplantation 
was chronic liver failure except one recipi[INVESTIGATOR_346800]-transplantation for hepatic artery thrombosis. 
The underlying etiology of liver disease was hepatitis C virus infection (n=6), alcoholic liver disease (n=5), 
primary sclerosing cholangitis (n=3), primary biliary cirrhosis (n=2), ɑ1-antitrypsin deficiency (n=1), non-
alcoholic steatohepatitis (n=1), chronic autoimmune hepatitis (n=1) and other cholangiopathic disease (n=1). 
Two matched control subjects were identified for each test subject using pre-set criteria. The median recipi[INVESTIGATOR_346801] 12 (7 – 27) in NMP vs. 14 (6 – 25) in matched controls.  
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 24 of 57 
CONTROLLED COPY Median NMP time was 9.31 (range from 3.5 to 18.5) hours. Median cold ischemia time (CIT) in the matched 
controls was 8.9 (range 4.2 – 11.4) hours. The period of NMP was governed by [CONTACT_346883] 
(mainly other transplants). There was evidence of stable hemodynamics, synthetic and metabolic function 
throughout all perfusions with maintenance of pH between 7.2 and 7.4 (unsupported). Bile production 
commenced after the first hour and was maintained, with an upward trend, throughout NMP. Hepatic arterial 
and portal venous flows were consistent throughout. 
Median ITU and hospi[INVESTIGATOR_346802]. All grafts and subjects in the NMP group survived the first 30 days but 1 recipi[INVESTIGATOR_22874] a 
DBD liver in the matched control group died on day 0 from a cardiovascular event. There was no primary non-
function in either group. Three subjects (15%) demonstrated EAD in the NMP group compared to 9 (22.5%) in 
the control group. This difference was more pronounced in the DCD subset (1 (25%) vs. 4 (50%) subjects). EAD 
in the NMP group was due to: day 7 bilirubin of 211 (liver 8, donor age 77); peak AST of 2158 (liver [ADDRESS_430840] of 1300); peak AST of 4681 (liver 16, DCD, age 53, WIT 27 minutes). There was a statistically 
significant difference in peak AST levels (417 vs. 902, p=0.034), numerically more pronounced in the DCD 
cohort (422 vs. 1894, p=0.283) . In all these cases, perfusion parameters were stable with good acid-base 
maintenance (indicators of good outcome). Postoperatively, all subjects made good recoveries.  
3. OBJECTIVES  
3.1 HY POTHESIS  
Normothermic machine perfusion (NMP) is superior to static cold storage (SCS) of human liver allografts for 
reduction of preservation injury. 
3.2  OBJECTIVES AND OUTCOME MEASURES /ENDPOINTS  
3.2.[ADDRESS_430841] of NMP to SCS in the prevention of preservation injury and graft dysfunction, as 
measured by [CONTACT_346857] (EAD). 
3.2.2  PRIMARY OUTCOME MEASURE /ENDPOINT  
The severity of immediate graft injury as measured by [CONTACT_346857] (EAD) [ 40]. The study will be 
powered to demonstrate a reduction in EAD from 25% to 10% in NMP versus SCS. EAD is a binary outcome 
defined by [CONTACT_107191] 3 outcomes: 
1. Serum bilirubin ≥ 10 mg/dL at day [ADDRESS_430842] -transplant  
2. International normalized rat io ≥ 1.[ADDRESS_430843] > 2000 IU/L within the first [ADDRESS_430844]-transplant  
 
 Objectives  Outcome measures/endpoints  
Primary  To compare the effec t of NMP to SCS in 
preventing preservation -related graft 
injury  Severity of immediate graft injury  as 
measured by [CONTACT_346857]  
(EAD). 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430845]  survival 
between NMP and SCS livers.  Primary non -function  rates : irreversible 
graft dysfunction requiring emergency 
liver replacement during the first [ADDRESS_430846] -
reperfusion syndrome between NMP 
and SCS livers on transplantation . Assess mean arterial pressure (MAP) 
pre- and post -reperfusion and 
requirement for vasopressor use.  
To compare biochemical liver function 
between NMP and SCS livers.  Bilirubin, GGT , ALT, AST, ALP and IN R at 
days [ADDRESS_430847] histological criteria.  
To compare evidence of  biliary 
complications  between NMP and SCS 
livers.  Incidence of biliary investigations and/or 
interventions between [ADDRESS_430848] -transplant . 
To assess the feasibility and safety of 
NMP as a method of organ storage and 
transportation.  Incidence of livers randomized but not 
transplanted and reasons for not -
transplanting.  
To compare organ utili zation between 
NMP and SCS.   Incidence of one or more of the 
following  per randomized liver : (i) EAD; 
(ii) discard (non -transplant) of a 
retrieved liver ; (iii) primary non -function . 
To assess the health economic 
implications of normothermic liver 
perfusion.  Logistical and healthcare costs ( length of 
stay in ICU and hospi[INVESTIGATOR_307])  and quality of 
life measures.  
 
4. TRIAL DESIGN  
This is a randomized controlled, non-blinded, clinical trial comparing SCS versus NMP for organ preservation 
prior to liver transplantation. Following assessment of donor and recipi[INVESTIGATOR_346803], the donor liver will be randomized to either NMP or SCS.  At the end of preservation, the liver will be 
transplanted and the enrolled recipi[INVESTIGATOR_346804]. 
Subjects are considered enrolled in the study when there is an attempt to transplant a randomized liver. 
Enrolled subjects who are transplanted with a randomized liver will participate in the study for a duration of 12 
months. If there is an attempt to transplant a randomized liver, but the liver is ultimately not transplanted, the 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430849] .  
If the intended original recipi[INVESTIGATOR_346805], the liver will be offered to the next 
recipi[INVESTIGATOR_346806].  All attempts by [CONTACT_346884] a local recipi[INVESTIGATOR_346807]/exclusion 
criteria for the study.  In situations where this is not possible, emergency use procedures may be followed in 
accordance to FDA regulations should the liver be randomized to the investigational device arm (NMP).    
Primary and secondary outcomes will be analyzed and reported after all available transplanted subjects have 
completed the [ADDRESS_430850] for liver-only transplantation at any of 
the participating transplant centers. 
5.2.1  CMS  REIMBURSEMENT  
Based on the target study population, approximately 30% of subjects enrolled will utilize CMS/Medicare 
reimbursement during their participation. It is not anticipated that the device under investigation will treat a 
Medicare population different than the demographics found in the investigators' general population for this 
same condition, including populations eligible for Medicare due to age (e.g., 65 years or older), disability, or 
other eligibility status. The demographics of recipi[INVESTIGATOR_346808]-Medicare populations. According to the American Liver Foundation, at least [ADDRESS_430851] hepatitis C. In addition, about 21,000 Americans are 
diagnosed with primary liver cancers, one of the few cancers on the rise in the U.S. The Centers for Disease 
Control and Prevention (CDC) stated that more than 75 percent of adults with hepatitis C are born between 
1945 and 1966 and it is estima ted that one in every 33 “baby [CONTACT_346885] s” has viral hepatitis and are five times 
more likely to have hepatitis C. While these numbers indicate a rise in the incidence of liver disease, it is 
anticipated the number of liver transplants will also rise in both the Medicare and Non-Medicare 
populations. The number of liver transplants has increased by 10% in all ages and 7.3% in the Medicare 
population in the last ten years. The recipi[INVESTIGATOR_346809]. Several demographic measures (e.g., age, weight, 
race/ethnicity, functional status, geography, etc.), cause of death, function of liver, and recovery time and 
logistics will impact the outcome of the recipi[INVESTIGATOR_841]. Thus the results of the study are expected to be 
generalizable to the Medicare eligible population and a logistic regression model will be used to examine the 
possible explanatory effect of Medicare recipi[INVESTIGATOR_266653].  
 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430852] be met at the time of a recipi[INVESTIGATOR_346810] a donor and the donor liver 
receiving a randomization assignment. 
5.3.1  DONOR CRITERIA  
5.3.1 .1 DONOR INCLUSION CRITERIA  
1. DBD donor aged 40 years or greater  
2. DCD donor aged 16 years or greater  
3. Liver allograft from donation after brain death (DBD) or donation after circulatory death (DCD) donors  
[IP_ADDRESS]  DONOR EXCLUSION CRITERIA  
1. Living donor liver 
2. Liver intended for split transplant 
3. Liver which Investigator is unwilling to randomize to either arm 
5.3.2  RECIPI[INVESTIGATOR_346811]  
[IP_ADDRESS]  RECIPI[INVESTIGATOR_346812]   
1. Subject is [ADDRESS_430853] is able and willing to comply with all study requirements (in the opi[INVESTIGATOR_689]) 
[IP_ADDRESS]  RECIPI[INVESTIGATOR_346813]  
1. Subject requiring all of the following  at the time of transplantation: 
a. Oxygen therapy via a ventilator/respi[INVESTIGATOR_13521] 
b. Inotropic support 
c. Renal replacement therapy 
2. Subject has acute/fulminant liver failure (UNOS status 1A) 
3. Subject undergoing simultaneous transplantation of more than one organ (e.g., liver and kidney) 
4. Subject is pregnant (as confirmed by [CONTACT_346886]) or nursing 
5. Concurrent enrollment in another clinical trial.  Subjects enrolled in clinical trials or registries where 
only measurements and/or samples are taken (NO TEST DEVICE or TEST DRUG USED) are allowed to 
participate. 
6. TRIAL PROCEDURES  
The participant timeline is illustrated in Appendix A1.  The following section provides details of this timeline 
and all study procedures. 
6.1 RE CRUITMENT  
The emergency nature of liver transplantation means that once a potential recruit/study subject is called in for 
a transplant there will only be a 3-[ADDRESS_430854] to fully consider his/her participation in the study. For this 
reason, all p atients who fulfil the entry criteria and who are on the UNOS waiting list for liver transplantation 
at the participating cent ers should  be provided with full information  either during a routin e clinic 
appointment, inpatient admission , or a mailed copy of the Informed Consent Form in accordance with local IRB 
policy . Informed consent will then be requested at the time the patient is admitted for transplantation.  
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 28 of 57 
CONTROLLED COPY Alternatively, depending on local factors (including the size of waiting list) it may logistically be possible for 
patients to be informed and to provide consent while on the waiting list (in advance of the donor organ 
becoming available). 
6.2 IN FORMED CONSENT  
6.2.1 RECIPI[INVESTIGATOR_346814], subjects (or their legally authorized representative) must consent 
to participate after the nature, scope, and possible consequences of the clinical study have been explained in a 
form understandable to them and per the requirements in [ADDRESS_430855]. Subjects are free to withdraw consent at any time, irrespective of their initial 
consent.    
After reading the informed consent document, the participant (or their legally authorized representative) must 
sign and date the current approved version of the informed consent form before any study specific procedures 
are performed. Written and verbal versions of the informed consent form will be presented to the participants 
detailing the exact nature of the study, the implications and constraints of the protocol, and any risks involved 
in taking part. It will be clearly stated that the participant is free to withdraw from the study at any time for 
any reason without prejudice to future care, and with no obligation to give the reason for withdrawal. The 
participant will be allowed as much time as possible to consider the information, and the opportunity to 
question the Investigator, or other members of the clinical or research team, to decide whether to participate 
in the study.  
 
The study coordinator at each center will maintain a list of consenting subjects. 
 
Any use of the device without obtaining informed consent shall be promptly reported (no later than 5 working 
days) to the US Sponsor and the IRB.  
 
A copy of the signed consent document must be offered to the subject. The original signed consent document 
will be retained by [CONTACT_737].  
 
The Investigator will not perform any exams or testing specifically required only for the clinical study until valid 
consent has been obtained.  
 
The Investigator may inform the subject’s primary physician about the subject’s participation in the trial if the 
subject has a primary physician and if the subject agrees to the primary physician being informed. 
6.2.[ADDRESS_430856] practices from the retrieving Organ 
Procurement Organization (OPO). 
During the course of the study, donor details will be kept anonymous (specific study identification codes will 
be used for each study donor).  Donor data will only be made available to authorized staff of the study 
Sponsor, its authorized representatives, and the FDA. 
 
 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430857] in participating centers will be screened for suitability for 
transplantation; beyond fulfilling the inclusion/exclusion criteria listed above, further screening assessment is 
not required as part of the trial and the subject will be followed per standard of care . Upon the offer of a 
suitable donor organ, consent will be requested as described in section 6.2.1, if it has not already been 
obtained.   
6.3.2  DONOR ASSESSMENT  
On reciept of an organ offer, the local recipi[INVESTIGATOR_346815]. The decision 
whether to transplant a liver in this study remains solely the responsibility of the Investigator. 
6.4 RA NDOMI ZATION AND BLINDING  
6.4.1  SEQUENCE GENERATION  
Donor livers will be randomly assigned to NMP or SCS with 1:1 allocation as per a computer generated 
randomization schedule using variable block randomization using the following stratification factors: 
participating (recipi[INVESTIGATOR_841]) center and by [CONTACT_136866] (DBD or DCD). The randomization schedule will be created 
by [CONTACT_4305], and will remain confidential.  
6.4.[ADDRESS_430858] has been recruited to the trial and donor and recipi[INVESTIGATOR_346816]/exclusion criteria 
have been recorded.  Random permuted block length will be used; block sizes will not be disclosed. 
6.4.3 IMPLEMENTATION  
Prior to randomization, the local Investigator will confirm the availability of the investigational metra®  device. 
Once informed consent has been verified from the potential recipi[INVESTIGATOR_346817], the local recipi[INVESTIGATOR_346818].  Recipi[INVESTIGATOR_346819] a randomized liver has been assigned 
and there is an attempt to transplant the randomized liver. 
6.4.4  BLINDING /MASKING  
While it is not possible to blind the local Investigators to the method of organ preservation, Histopathologists 
at the central laboratory interpreting the biopsy specimens will remain blinded to the randomization group to 
the extent possible. 
6.5 PRE- S TUDY BASELINE ASSESSMENTS  
Pre-study baseline assessments to be completed include the following: 
6.5.1  DONOR DEMOGRAPHICS  
Retrieving OPOs/investigational sites will collect donor information per the Organ Procurement and 
Transplantation Network (OPTN) Policy.  
In addition to the OPTN Policy requirements listed in Section 2.11.B, the following will be collected: 
1. Age 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 30 of 57 
CONTROLLED COPY 2. Sex 
3. Race 
4. Ethnicity 
5. Cause of death (CVA, hypoxia, trauma, other) 
6. Type of donor (DBD, DCD) 
7. Donor height 
8. Donor risk index (DRI) [ 3] 
9. Last and peak serum AST 
10. Last and peak serum sodium 
11. Last and peak GGT 
12. Length of ICU stay 
13. BMI 
6.5.2  RECIPI[INVESTIGATOR_346820], but not be limited to, the following: 
1. Age 
2. Sex 
3. Race 
4. Ethnicity 
5. Etiology of liver disease 
6. Indication for transplant 
7. MELD score  
8. UNOS status 
9. BMI 
10. Relevant medical history 
11. Relevant social history 
6.5.3  QUALITY OF LIFE QUESTIONNAIRE (EQ-5D-5L) 
Recipi[INVESTIGATOR_346821] (measured by [CONTACT_346887]- 5D-5L).  
6.6 TR IAL INTERVENTIONS  
6.6.1  NMP  GROUP  (INVESTIGATIONAL METRA ® DEVICE ) 
If the liver is randomized to the NMP group, arrangements will be made to transport the device to the donor 
hospi[INVESTIGATOR_307] (see section 7.6 ).  The recipi[INVESTIGATOR_346822] 3 units of donor-type red blood cells 
to be available for use in the OrganOx metra®  device.  Following the routine retrieval procedure at the donor 
hospi[INVESTIGATOR_346823]-cold perfusion solution (according to local protocol) on the back-table, 
and prepared for cannulation. The procedure for preparing the device for use and placing the organ on the 
device is described in detail in the metra®  Instructions for Use (IFU) document.  The device is then transported 
to the recipi[INVESTIGATOR_346824].  The procedure for removing the liver from the device is 
also described in the IFU.  Transplantation and reperfusion of the liver proceed as per the usual practice of the 
transplanting center.  The duration of machine perfusion will be dictated by [CONTACT_346888], but 
should not be less than [ADDRESS_430859] of the Principal Investigator [INVESTIGATOR_346825], a representative from OrganOx that is trained on the 
OrganOx metra®  may: 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 31 of 57 
CONTROLLED COPY  Provide technical expertise on the use and functionality of the OrganOx metra®  device and 
testing that will be conducted as part of the study 
 Be present during the procurement of the donor liver and recipi[INVESTIGATOR_346826] 
 Prepare the system for use and assist with use of the OrganOx metra®  device 
6.6.2  SCS  GROUP  
Following the routine retrieval procedure, the liver will be placed in ice-cold perfusion solution (according to 
local protocols) on the back-table, followed by [CONTACT_346889].   The organ 
will be transported to the recipi[INVESTIGATOR_346827], and removed from storage prior to 
transplantation for standard back-table preparation.  The duration of cold storage will be dictated by [CONTACT_346890]. 
6.6.[ADDRESS_430860] the following data: 
[IP_ADDRESS]  DONOR TIMINGS  
[IP_ADDRESS].1  DBD  DONOR TIMINGS  
The following times will be recorded for DBD donors: 
1. Brain Death declaration (date and time) 
2. Cessation of donor circulation (cross clamp date and time) 
3. Start of cold perfusion 
4. Liver removal and placement on ice 
5. Removal from ice (recipi[INVESTIGATOR_346828]) 
6. Portal reperfusion 
7. Arterial reperfusion 
[IP_ADDRESS].2  DCD  DONOR TIMINGS  
The following times will be recorded for DCD donors: 
1. Withdrawal of support (oxygen therapy and/or inotropic if applicable) 
2. Onset of functional warm ischemia (SBP < 50 mmHg) 
3. Time of Cardiac Death 
4. Start of cold perfusion 
5. Liver removal and placement on ice 
6. Removal from ice (recipi[INVESTIGATOR_346828]) 
7. Portal reperfusion 
8. Arterial reperfusion 
[IP_ADDRESS].3  DBD/ DCD  DONOR TIMINGS  RANDOMIZED TO NMP  
In addition to all above parameters, the following will be recorded for all donor livers randomized to NMP: 
1. Initiation of normothermic machine preservation 
2. Cessation of normothermic machine perfusion (cold flush) 
[IP_ADDRESS]  PRESERVATION PARAMETERS FOR ALL RANDOMIZED LIVERS  
The following preservation parameters will be collected for all randomized livers:  
1. Degree of steatosis (graded mild, moderate, severe) – surgeon’s assessment  at time of retrieval 
2. Quality of in-situ  perfusion (graded poor, moderate, good) 
3. Perfusion parameters for NMP livers (these are logged automatically by [CONTACT_8121]): 
a. Arterial, and IVC pressures (mmHg) 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 32 of 57 
CONTROLLED COPY b. Arterial, portal and caval flow rates (ml/min) 
c. pO 2, pCO 2 and pH 
d. Blood temperature (oC), glucose (mmol/L) and bile production (ml/h) 
4. Perfusate ALT and AST (for NMP livers) 
5. Lactate values and time obtained at the following time points (for NMP livers):  
a. After approximately 15 minutes of NMP  
b. Following arrival at the transplant hospi[INVESTIGATOR_307] 
c. Following the end of NMP  
6. Perfusion solution used for in situ  and back-bench  perfusion (all livers) 
Perfusion solution used for organ transport (SCS livers only) 
7. Glucose values measured using i_STAT or similar FDA approved diagnostic device at the following 
time points (for NMP livers): 
a. Approximately after 15 minutes of NMP  
b. Approximately every 4 hours thereafter during perfusion 
At the end of preservation a sample of perfusate/storage solution will be taken for microbiological culture (SCS 
and NMP groups). 
[IP_ADDRESS]  OPERATIVE PARAMETERS  
These will include: 
1. Total operative time: defined as time from knife- to-skin to wound closure. 
2. Anastomotic time (secondary warm ischemia): defined as time between removal of organ from 
ice (SCS) or perfusion device (NMP) to organ reperfusion (whichever is first of portal or arterial) 
3. Occurrence of post-reperfusion syndrome (defined as a decrease in mean arterial pressure (MAP) 
of more than 30% from the baseline value for more than one minute during the first five minutes 
after reperfusion [ 41, 42]) 
4. Use of vasopressors prior to and after reperfusion 
5. Intraoperative transfusion of blood and blood products (measured in units) 
6. The use of veno-venous by[CONTACT_346891]-caval shunts 
7. Type of caval anastomosis : end- to-end caval replacement, pi[INVESTIGATOR_346829] (end-side or side-side) 
[IP_ADDRESS]  HISTOLOGICAL PARAMETERS  
Graft biopsies will be completed on both groups and will be taken: 
1. Pre-Storage (Baseline) : Before being placed for storage in either NMP or SCS  
2. Post-Storage:  
a. Following storage in either NMP or SCS 
b. Immediately prior to abdominal closure  
 
The post-storage biopsies will be compared to the pre-storage (baseline) biopsy, examined for evidence of 
reperfusion injury, and graded according to standard histological criteria [39, 43]. For this analysis a  central  
core lab oratory  will be used where the histopa thologist will be blinded to the method of storage . 
6.[ADDRESS_430861]-transplant monitoring will follow local protocols. 
 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430862] local protocols (refer 
to Appendix A1 for Visit Windows). 
[IP_ADDRESS]  BIOCHEMICAL ASSESSMENTS   
The following biochemical outcomes will be recorded where the first measurements should be taken between 
12 and 24 hours of reperfusion: 
1. Daily samples for the first [ADDRESS_430863]-transplant, to include: 
a. Total serum bilirubin (measured in mg/ dL) 
b. Serum alkaline phosphatase (ALP; measured in IU/L) 
c. Serum gamma-glutamyl transferase (GGT; measured in IU/L)* 
d. Serum aspartate transaminase (AST; measured in IU/L) 
e. Serum alanine aminotransferase (ALT; measured in IU/L) 
f. PT/International normalized ratio (INR) 
g. Serum albumin (measured in g/dL)* 
h. Serum creatinine (measured in mg/dL)* 
2. Daily serum lactate (measured in mmol/L) while admitted to ICU* 
*Only collected if Standard of Care  
[IP_ADDRESS]  ADDITIONAL ASSESSMENTS  
The following additional data will be collected and recorded: 
1. Length of stay in high level care (ICU) (days) 
2. Total length of hospi[INVESTIGATOR_4408] (days) 
3. Total number of ventilation days post-transplant  
4. Requirement for renal replacement therapy (Hemodialysis (HD) , Hemodiafiltration (HDF), 
Hemofiltration (HF)) 
5. Primary non-function: irreversible graft dysfunction requiring emergency liver replacement during the 
first 10 days after liver transplantation. 
[IP_ADDRESS]  SAFETY ASSESSMENTS  
The following safety data will be collected and recorded: 
1. Recipi[INVESTIGATOR_346830] (documented positive microbiological culture, pathological lesion, or clinical 
criteria met) 
2. Biopsy-proven acute rejection epi[INVESTIGATOR_1841] 
3. Biliary investigations (MRCP, ERCP, PTC)  
4. Biliary interventions (surgical, radiological, or endoscopic) 
5. Hepatic v ascular comp lications ( e.g., hepatic artery stenosis, hepatic artery thrombosis, portal vein 
thrombosis, portal vein stenosis)  
6. Acute Hemorrhage  (requiring transfusion of two or more units of red blood cells)  
7. Reoperation for graft related complications 
8. Adverse event(s) 
[IP_ADDRESS]  IMMUNOSUPPRESSION  
Details of induction and maintenance immunosuppression at day [ADDRESS_430864]-TRANSPLANT PROCEDURE  
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 34 of 57 
CONTROLLED COPY This visit will, where possible, coincide with a routine outpatient appointment.  If the recipi[INVESTIGATOR_346831], 
assessment will be made in hospi[INVESTIGATOR_346832] (refer to Appendix A1 for Visit Windows). 
[IP_ADDRESS]  BIOCHEMICAL ASSESSMENTS  
The following biochemical outcomes will be recorded at day [ADDRESS_430865]-transplant: 
1. Total serum bilirubin (measured in mg/dL ) 
2. Serum alkaline phosphatase (ALP; measured in IU/L) 
3. Serum gamma-glutamyl transferase (GGT; measured in IU/L)* 
4. Serum aspartate transaminase (AST; measured in IU/L) 
5. Serum alanine aminotransferase (ALT; measured in IU/L) 
6. PT/International normalized ratio (INR) 
7. Serum albumin (measured in g/dL)* 
8. Serum creatinine (measured in mg/dL)* 
*Only collected if Standard of Care 
[IP_ADDRESS]  ADDITIONAL ASSESSMENTS  
The following additional data will be collected and recorded: 
1. Graft and subject survival at day [ADDRESS_430866]-transplant 
2. Requirement for renal replacement therapy (HD, HF, HDF) for more than a total of five days 
3. Length of hospi[INVESTIGATOR_4408] 
4. Readmissions 
5. Healthcare resource use (by [CONTACT_346892][INVESTIGATOR_346833]) 
[IP_ADDRESS]  SAFETY ASSESSMENTS  
The following safety data will be collected and recorded:  
1. Recipi[INVESTIGATOR_346830] (documented positive microbiological culture, pathological lesion, or clinical 
criteria met) 
2. Biopsy-proven acute rejection epi[INVESTIGATOR_1841] 
3. Biliary investigations (MRCP, ERCP, PTC)  
4. Biliary interventions (surgical, radiological, or endoscopic) 
5. Hepatic vascular complications (e.g., hepatic artery stenosis, hepatic artery thrombosis, portal vein 
thrombosis, portal vein stenosis) 
6. Reoperation for graft related complications 
7. Adverse event(s) 
[IP_ADDRESS]  IMMUNOSUPPRESSION  
Details of maintenance immunosuppression at day [ADDRESS_430867]-TRANSPLANT PROCEDURE  
This visit will, where possible, coincide with a routine outpatient appointment.  If the recipi[INVESTIGATOR_346831], 
assessment will be made in hospi[INVESTIGATOR_346832] (refer to Appendix A1 for Visit Windows). 
[IP_ADDRESS]  BIOCHEMICAL ASSESSMENTS  
The following biochemical outcomes will be recorded at month [ADDRESS_430868]-transplant: 
1. Total serum bilirubin (measured in mg/dL) 
2. Serum alkaline phosphatase (ALP; measured in IU/L) 
3. Serum gamma-glutamyl transferase (GGT; measured in IU/L)* 
4. Serum aspartate transaminase (AST; measured in IU/L) 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 35 of 57 
CONTROLLED COPY 5. Serum alanine aminotransferase (ALT; measured in IU/L) 
6. PT/International normalized ratio (INR) 
7. Serum albumin (measured in g/dL)* 
8. Serum creatinine (measured in mg/dL)* 
*Only collected if Standard of Care 
[IP_ADDRESS]  ADDITIONAL ASSESSMENTS  
The following additional data will be collected and recorded: 
1. Graft and subject survival at month [ADDRESS_430869]-transplant 
2. Requirement for renal replacement therapy (HD, HF, HDF ) for more than a total of five days  
3. Readmission(s) 
4. Healthcare resource use (by [CONTACT_346892][INVESTIGATOR_346833]). 
[IP_ADDRESS]  SAFETY ASSESSMENTS  
The following safety data will be collected and recorded: 
1. Recipi[INVESTIGATOR_346830] (documented positive microbiological culture, pathological lesion, or clinical 
criteria met) 
2. Biopsy-proven acute rejection epi[INVESTIGATOR_1841] 
3. Biliary investigations (MRCP, ERCP, PTC)  
4. Biliary interventions (surgical, radiological, or endoscopic) 
5. Hepatic vascular complications (e.g., hepatic artery stenosis, hepatic artery thrombosis, portal vein 
thrombosis, portal vein stenosis) 
6. Reoperation for graft related complications 
7. Adverse event( s) 
[IP_ADDRESS]  IMMUNOSUPPRESSION  
Details of maintenance immunosuppression at month [ADDRESS_430870]-TRANSPLANT PROCEDURE  
This visit will, where possible, coincide with a routine outpatient appointment.  If the recipi[INVESTIGATOR_346831], 
assessment will be made in hospi[INVESTIGATOR_346832] (refer to Appendix A1 for Visit Windows). 
[IP_ADDRESS]  BIOCHEMICAL ASSESSMENTS  
The following biochemical outcomes will be recorded at month [ADDRESS_430871]-transplant: 
1. Total serum bilirubin (measured in mg/dL) 
2. Serum alkaline phosphatase (ALP; measured in IU/L) 
3. Serum gamma-glutamyl transferase (GGT; measured in IU/L)* 
4. Serum aspartate transaminase (AST; measured in IU/L) 
5. Serum alanine aminotransferase (ALT; measured in IU/L) 
6. PT/International normalized ratio (INR) 
7. Serum albumin (measured in g/dL)* 
8. Serum creatinine (measured in mg/dL)* 
*Only collected if Standard of Care 
[IP_ADDRESS]  ADDITIONAL ASSESSMENTS  
The following additional data will be collected and recorded: 
1. Graft and subject survival at month [ADDRESS_430872]-transplant 
2. Requirement for renal replacement therapy (HD, HF, HDF) for more than a total of five days 
3. Readmission(s) 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 36 of 57 
CONTROLLED COPY 4. Healthcare resource use (by [CONTACT_346892][INVESTIGATOR_346833]). 
5. Quality of life (measured by [CONTACT_346887]- 5D-5L questionnaire). 
[IP_ADDRESS]  SAFETY ASSESSMENTS  
The following safety data will be collected and recorded:  
1. Recipi[INVESTIGATOR_346830] (documented positive microbiological culture, pathological lesion, or clinical 
criteria met) 
2. Biopsy-proven acute rejection epi[INVESTIGATOR_1841] 
3. Biliary investigations (MRCP, ERCP, PTC)  
4. Biliary interventions (surgical, radiological, or endoscopic) 
5. Hepatic vascular complications (e.g., hepatic artery stenosis, hepatic artery thrombosis, portal vein 
thrombosis, portal vein stenosis) 
6. Reoperation for graft related complications 
7. Adverse event(s) 
[IP_ADDRESS]  IMMUNOSUPPRESSION  
Details of maintenance immunosuppression at month [ADDRESS_430873]-TRANSPLANT PROCEDURE  
This visit will, where possible, coincide with a routine outpatient appointment, but may be completed 
remotely via telephone.  If the recipi[INVESTIGATOR_346831], assessment will be made in hospi[INVESTIGATOR_346832] 
(refer to Appendix A1 for Visit Windows). 
1. Graft and subject survival at month [ADDRESS_430874]-transplant 
2. Requirement for renal replacement therapy (HD, HF, HDF ) for more than a total of five days  
3. Readmission(s) 
4. Healthcare resource use (by [CONTACT_346892][INVESTIGATOR_346833]). 
6.9  PA RTICIPANT RETENTION  
All transplanted subjects completing the 12 month follow-up assessment will be regarded as having completed 
the study.   All subjects will be encouraged to complete study follow-up, and all reasonable efforts will be made 
to ensure completeness of follow-up.  Measures include ensuring that assessments are made, where possible, 
at routine hospi[INVESTIGATOR_346834] (e.g., travelling costs) as a result of study participation. 
Every effort should be made to secure follow-up data on enrolled subjects. A subject will be considered Lost to 
Follow-Up if there are three documented contact [CONTACT_346893] (via phone, email, or certified mail) 
requesting follow- up with no response.  
I
t is understood that study subjects may withdraw consent for study participation at any time irrespective of 
their reasons.  The Investigators may also withdraw a subject from the study in order to protect the subject’s 
safety and/or if they are unwilling or unable to comply with the required study procedures. 
In the event of a subject withdrawing from the trial, the reason for withdrawal must be documented on the 
eCRF.  
6.[ADDRESS_430875]-transplant for safety. 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430876]-transplant follow-up visits, a final clinical study report will be completed 
and all subjects exited from the study. 
The procedures for the early termination/suspension of the study at one or more clinical sites (as a 
consequence of safety or compliance concerns) are detailed in section 8.3. 
7. THE ORGAN OX METRA ® DEVICE  
7.1 DE VICE DESCRIPTION  
7.1.1  THE ORGAN OX METRA ® BASE UNIT 
The OrganOx metra®  normothermic perfusion device incorporates a centrifugal pump, an oxygenator, oxygen 
concentrator, heat exchanger, reservoir, flow probes, pressure sensors, infusions and blood gas analyzer 
together with tubing and connector components. The device is comprised of three main components: 
1. Reusable base unit which contains software and hardware 
2. Disposable plastic circuit 
3. Set of perfusion solutions suitable for 24 hours of perfusion 
7.1.2  DISPOSABLE SET 
The disposable set used with the core base unit of the OrganOx metra®  contains all the disposables used with 
each organ recovery on the metra®  and comprises: 
1. A tubing set, including a blood reservoir, perfusion lines, a blood oxygenator/heat exchanger and 
centrifugal pump-head together with flow and pressure sensors. 
2. A liver bowl which is pre -connected to the tubing set to contain the organ while on the device.  
3. Cannulae  for the celiac artery, portal vein,  and inferior vena cava with easy connection attachment to the 
perfu sion circuit.  
4. A cannula and connection point for bile collection 
5. Blood gas sensors for monitoring pO 2, pCO 2, and pH by [CONTACT_321176]-line blood gas analysis. 
7.1.3  PERFUSION SOLUTIONS  
For the present study none of the additives necessary to perfuse and maintain the organ during the storage 
process, with the exception of sodium taurocholate, are included and will be sourced locally (OrganOx will 
provide a list of recommended suppliers in the Instructions for Use (IFU) document). These solutions include 
bolus injections (given at the start of perfusion) and the maintenance infusions (given throughout perfusion). 
The primary perfusion fluid for the liver comprises packed red blood cells, supplemented by [CONTACT_346894] .  
Before connection of the liver the blood-based perfusate is supplemented with: 
1. Antibiotic – e.g., Cefuroxime  
2. Heparin. 
3. Calcium gluconate. 
During the perfusion the following are infused at a constant rate: 
1. Nutrition – (Clinimix E) amino acids plus electrolytes. 
2. Insulin.  
3. Bile Salts. 
4. Flolan® (epoprostenol Prostacyclin). 
The primary fluid for perfusing the organ is packed red cells supplie d per local arrangements and 
supplemented by [CONTACT_346895]. Further additions are made to 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 38 of 57 
CONTROLLED COPY the perfusate to support the liver (in a similar mode to current preservation solutions such as Viaspan® or 
those used in machine preservation devices such as the Waters RM3® or the Organ Recovery Systems 
LifePort®). All solutions required will be attached to the circuit during set-up and before the liver is attached. 
The investigational study team will provide the solutions necessary for perfusion with the metra® . Solutions 
are prepared immediately before the organ is attached to the device and contain sufficient solution for 24 
hours of operation, the intended maximum perfusion time for a liver on the device. 
Sodium Taurocholate (bile salts) will be prepared in advance by [CONTACT_3878]’s  pharmacy in accordance 
with the Instructions for Use.    
7.2 DE VICE SAFETY  
In designing the metra® , OrganOx has made every attempt to maintain the current practices of organ retrieval 
and transplant teams, in order to minimize the risk of complications or errors that would prevent a successful 
retrieval. From a regulatory standpoint, it is important to note that the metra®  is an organ preservation system 
and its use does not involve direct connection to either the donor or recipi[INVESTIGATOR_346835]. 
The device has been designed according to ISO [ZIP_CODE], the standard that stipulates the requirements for a 
comprehensive management system for the design and manufacture of medical devices. In addition ISO [ADDRESS_430877] be removed from the organ prior to transplant. 
Therefore following the completion of the perfusion, the perfusate is flushed out of the organ with HTK 
solution (or the preferred preservation solution of the transplanting center). 
7.3  DE VICE LABELLING  
All components of the OrganOx metra®  system (reusable base unit and disposable set) will be labelled 
“CAUTION  Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use ”. Labelling 
will also include the Sponsor /Manufacturer  name, contact [CONTACT_8972],  and a unique trial identifier.  
Additional labelling requirements will be followed in accordance with OPTN Policy Section 16.0. 
7.4 DE VICE ACCOUNTABILITY  
Device accountability will be undertaken at each local site throughout the study for the reusable unit(s) and 
disposable sets (sterilization/assembly batch number and disposable set number). The manufacturer and lot 
number for each perfusion solution will also be recorded on the eCRF. The site will maintain a log of the 
retained unit, disposable sets, and perfusion solutions used throughout the study recording the lot number 
used against each subject (on the eCRF).  
At the end of each procedure the OrganOx metra®  and any unused disposable and perfusion solutions will be 
removed from the donor hospi[INVESTIGATOR_346836] .  
7.5 DE VICE MAINTENANCE  
Device cleaning and routine maintenance will be the responsibility of the local Investigator storing the device.  
Full details for cleaning and routine maintenance required will be provided in the Instructions for Use (IFU), 
and appropriate training will be provided as part of the device training described in section 11.3. 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430878] be considered in using the OrganOx metra® : 
1. The device is large, and therefore, may not fit in normal retrieval transportation depending on local 
procedures. 
2. The device has a battery life of 2.5 hours, and so the mode of transport should provide a means of 
providing AC power. 
3. The device requires the manual measurement and entry of perfusate glucose every 4 hours during 
perfusion. 
7.6.2  LOGISTICAL ARRANGEMENTS FOR STUDY  SITES 
The OrganO x metra®  devi ce will be stored and maintained at the investigative site, or an approved delegated 
site. When an eligible donor organ is offered to the investigative site for a subject who consents to take part in 
the study , the recipi[INVESTIGATOR_346837]. 
The recipi[INVESTIGATOR_346838]/her of the 
randomization assignment.  If the liver has been randomized to machine perfusion, the recipi[INVESTIGATOR_346839]. The investigational study team will also arrange for [ADDRESS_430879] (DSMB), which consists of at least four independent 
members including clinicians with relevant expertise and a statistical expert, independent from the 
Investigators and the funding source. The DSMB will periodically review accruing data to safeguard the 
interests of the trial participants, potential participants, and future patients and assess the safety of the 
interventions.   
A separate DSMB charter will contain full details of the committee and its roles and reporting structure. 
8.1.[ADDRESS_430880] expanded 
enrollment in the study.   
8.2 AD VERSE EVENTS  
8.2.1  DEFINITIONS  
An Adverse Event (AE)  is defined as any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) whether or not related to the study 
intervention.  
A Serious Adverse Event (SAE) is defined as an adverse event that: 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 40 of 57 
CONTROLLED COPY  Led to death 
 Resulted in serious deterioration in the health of the subject that results in: 
o Life-threatening illness or injury , or 
o Permanent impairment of a body structure or a body function , or 
o The need for inpatient care or prolongation of hospi[INVESTIGATOR_059] , or 
o Medical or surgical intervention to prevent life-threatening illness or injury or permanent 
impairment to a body structure or a body function. 
Planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure required by [CONTACT_47519], without 
serious deterioration in health, is not considered a serious adverse event. 
An Unanticipated Adverse Device Effect (UADE)  is defined as any adverse device effect which, by [CONTACT_5942], 
incidence, severity or outcome, has not been identified in section 8.2.3. 
8.2.2  ADVERSE EVENT SEVERITY DEFINITIONS  
The following definitions will be used to determine the severity rating for all adverse events: 
Mild:  awareness of signs or symptoms, that does not interfere with the subject’s usual activity or is transient 
that resolved without treatment and with no sequelae. 
Moderate:  a sign or symptom, which interferes with the subject’s usual activity.  
Severe:  incapacity with inability to do work or perform usual activities. 
8.2. 3 ANTICIPATED ADVERSE EVENTS  
General 
 Infection (chest, urine, blood, bile, wound, abdominal) 
 Fluid collection (abdominal, pleural) 
 Rejection 
 Renal dysfunction 
 Hepatic dysfunction 
 Cardiac failure 
 Respi[INVESTIGATOR_346840] / condition / surgery 
 Early graft dysfunction 
 Admission for suspected rejection 
 Occurrence and treatment of abdominal or wound infection 
 Respi[INVESTIGATOR_61160] 
 Hospi[INVESTIGATOR_346841] -existing condition that has not deteriorated.  
 Clinically significant abnormal laboratory finding or other abnormal assessments that is associated 
with the disease being studied (unless judged by [CONTACT_346896] ’s condition).  
 Death 
The Investigator will exercise his/her medical judgment in deciding whether an abnormal laboratory finding or 
other abnormal assessment is clinically significant. However, if in the opi[INVESTIGATOR_689], the frequency 
or severity of the event is greater than would be expected then it must be reported. 
8.2.4  DEVICE DEFICIENCY  
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430881] led to a medical occurrence if suitable 
action had not been taken, or intervention had not been made or if circumstances had been less fortunate will 
also be managed as detailed in section 8.2.5. 
 
[IP_ADDRESS]  DEVICE FAILURES  
A device failure has occurred when the device is used in accordance with the IFU, but does not perform as 
described in the IFU and also negatively impacts treatment of the study subject.  
[IP_ADDRESS]  DEVICE MALFUNCTIONS  
A device malfunction occurs when an unexpected change to the device that is contradictory to the IFU is 
observed, which may or may not affect device performance.  
[IP_ADDRESS]  USE ERRORS  
A device use error is an a ct or omission of an act that results in a different medical device response than 
intended by [CONTACT_3460].  Use e rror includes slips, lapses , and mistakes.   An 
unexpected physiological response of the subject does not itself const itute a use error.  
8.2.5  PROCEDURES FOR RECORDING ADVERSE EVENTS  
It is the responsibility of the local Investigator to ensure that all adverse events (AEs , SAEs, UADEs, and device 
deficiencies) occurring during the course of the study are recorded. This may include but not be limited to: 
 A description of the event 
 The dates of the onset and resolution 
 Action taken 
 Outcome 
 Assessment of relatedness to the device 
 Assessment of relatedness to the transplant procedure 
 Severity 
 Whether the AE is serious or not 
 Whether the AE arises from device deficiency, device malfunction, or use error 
Adverse events that occur during the course of the study should be treated by [CONTACT_346897]. 
It is the responsibility of the local Investigator to collect all directly observed adverse events and all adverse 
events spontaneously reported by [CONTACT_423]. In addition, each subject should be questioned about adverse 
events at each visit.  Adverse events should be recorded on provided adverse event data collection forms. 
8.2. [ADDRESS_430882] (812.150). 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430883] (812.46(b)).  
The sponsor shall conduct an evaluation of an unanticipated adverse device effect under 812.46(b) shall report 
the results of such evaluation to FDA and to all reviewing IRB's and participating Investigators within [ADDRESS_430884] as FDA requests (812.150). 
8.[ADDRESS_430885] s experiencing an event (EAD or 30-day PNF 
or 30-day subject death) is greater in the NMP arm than that in the SCS arm by [CONTACT_346898].  
The sponsor shall consider terminating or suspending the participation of a particular study site or Investigator 
in the study if monitoring or auditing identifies serious or repeated deviations on the part of an Investigator. 
If suspension or premature termination occurs, the terminating party shall justify its decision in writing and 
promptly inform the other parties with whom they are in direct communication. The Principal Investigator [INVESTIGATOR_346842] (IRB) and/or a regulatory authority. 
If, for any reason, the sponsor suspends or prematurely terminates the study at an individual investigati ve site, 
the sponsor shall inform the FDA as appropriate and ensure that the IRB is notified, either by [CONTACT_9532] [INVESTIGATOR_10368]. If the suspension or premature termination was in the interest of safety, the 
sponsor shall inform all other Investigators. 
If suspension or premature termination occurs, 
a) The Sponsor/Manufacturer shall remain responsible for fulfilling the obligations from the study 
protocol and existing agreements for following subjects enrolled in the study as applicable, and 
b) The Principal Investigator [INVESTIGATOR_346843]/her study site, if appropriate, and follow written instructions provided by [CONTACT_429]/Manufacturer and the US Sponsor. 
9. STATISTICS  
This section provides a summary of the planned statistical analyses; additional detail will be contained in the 
Statistical Analysis Plan. In any apparent instances of ambiguity or disparity, the terms and procedures of the 
Statistical Analysis Plan (SAP) govern trial analyses. 
9.1 DE SCRIPTION OF  STATISTICAL METHODS  
9.1.1  GENERAL  STATISTICAL  CONSIDERATIONS  
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 43 of 57 
CONTROLLED COPY All statistical analyses will be performed using SAS version 9.3 or above (SAS Institute, Cary, N.C.) or another 
validated statistical software package. Unless otherwise specified, the data will be summarized in tables 
presenting the mean, standard deviation, and number of subjects in a group for continuous data, or presenting 
count and percentage analyzed using ANOVA with adjustment for categorical data, as appropriate.  
In general, binary data will be assessed using the chi- squared test (or Fisher’s Exact , if appropriate) or logistic 
regression to adjust for potential confounders. Continuous outcomes will be compared using the T-test if 
normally distributed, or by [CONTACT_346899]-Whitney U test.  Time- to-event outcomes will be analyzed using survival 
analysis methods, such as Kaplan-Meier or Cox proportional hazards regression model with calculation of 
hazard ratios.  Outcomes will be reported with 95% confidence intervals and p-values to [ADDRESS_430886]-transplant 
follow- up, although no formal statistical comparisons will be performed . T his summary will be strictly for FDA 
review to continue enrollment in the study.   
9.1.3  STUDY  COHORTS  FOR  ANALYSES  
A modified intent- to-treat (mITT) analysis will be performed for all outcomes as the primary analysis.  
Transplanted subjects ( a subject who has been reperfused with a donor liver) will be analyzed in the groups to 
which the liver received is randomly assigned, irrespective of whether the assigned method of preservation is 
actually used.  Practically, this means that if a liver intended by [CONTACT_346900], it will be analyzed in the assigned machine perfusion group.  Because analyses 
require data post-transplant, the analysis will exclude recipi[INVESTIGATOR_346844] a liver that was 
randomized, but were not transplanted for any reason.  In the case of DCD livers in which the retrieval did not 
proceed, the reason will be documented along with associated DCD recovery time points.  In all other cases 
the reason for the liver not proceeding to transplantation will be documented and a narrative summary of this 
data performed.   In cases of emergency use, where the liver is unable to be transplanted into the initial 
intended recipi[INVESTIGATOR_346845]-allocated to a recipi[INVESTIGATOR_346846], data will not be 
collected beyond what is provided to UNOS through the UNET database, and therefore, these subjects will not 
be included in any outcome analyses that are performed.  Recipi[INVESTIGATOR_346847], 
in these instances, will be summarized and reported separate from the study cohort on data available up to 
one-year post-transplant .  
As additional, supportive, analyses of the outcomes, a per-protocol (PP) cohort will be considered. This cohort 
will include all subjects who were followed according to the protocol procedures with no major deviations 
(beyond not being treated in the arm they were assigned to). 
9.1.4  PRIMARY OUTCOME  
The intervention (NMP) will be compared against control (SCS) for all primary and secondary outcomes in the 
mITT population.  
Primary outcome, difference in EAD, will be analyzed using a logistic model with adjustment for stratification 
factors. The hypothesis is: 
H0: EAD NMP ≥ EAD SCS 
HA: EAD NMP < EAD SCS 
In other words, the EAD for the NMP group is less than the EAD for the SCS group. 
EAD is a binary outcome defined by [CONTACT_107191] 3 outcomes [ 40]: 
1. Serum bilirubin ≥ 10 mg/dL at day [ADDRESS_430887]-transplant 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 44 of 57 
CONTROLLED COPY 2. International normalized ratio ≥ 1.[ADDRESS_430888] > 2000 IU/L within the first [ADDRESS_430889]-transplant 
 
The primary analysis will be a logistic model, adjusted for participating (recipi[INVESTIGATOR_841]) center using SAS PROC 
LOGISTIC or a similar procedure. Significance for the treatment effect will be assessed by [CONTACT_941] p-value 
associated with the F-test statistic for the treatment group assignment. 
 
9.1.5  SECONDARY OUTCOMES  
The following endpoints will be considered secondary endpoints for the study and will be summarized using 
the appropriate analyses described in section 9.1.1: 
1. To compare graft and subject survival between NMP and SCS livers 
2. To compare evidence of post-reperfusion syndrome between NMP and SCS livers on transplantation 
3. To compare biochemical liver function between NMP and SCS livers 
4. To compare evidence of ischemia-reperfusion injury between NMP and SCS livers 
5. To compare evidence of biliary complications between NMP and SCS livers 
6. To assess the feasibility and safety of NMP as a method of organ storage and transportation  
7. To compare organ utilization between NMP and SCS livers  
8. To assess the health economic implications of normothermic liver perfusion  
 
Additionally, a logistic model will be used to examine the possible explanatory effects of baseline subject 
characteristics (in the presence of the treatment indicator variable), namely:  race, age, gender, and number of 
liver transplants received (primary or secondary).   
Secondary analysis may be stratified by [CONTACT_110871][INVESTIGATOR_346848] (DBD or DCD) for exploratory 
purposes.  
9.1.6  SAFETY ANALYSES  
Safety data will be collected and reported on for those recipi[INVESTIGATOR_346849] a randomized liver and 
there is an attempt to transplant the randomized liver . 
9.1.7  SUBGROUP ANALYSES  
Subgroup analyses will be performed for donor type (DCD vs. DBD), by [CONTACT_346901] (DRI), and by [CONTACT_346902].   
Full details of the proposed statistical analysis will be outlined in a separate Statistical Analysis Plan ( SAP).    
9.1.8  POOLABILITY ANALYSIS  
Poolability analyses will be performed on the primary endpoint to assess whether results are poolable across 
participating centers.  
A logistic model with EAD as the dependent (outcome) variable will be reported using a binary treatment 
indicator variable and site by [CONTACT_165572](s) as independent variables to assess poolability of 
data across sites. Absence of statistically significant interaction term(s) (using a p-value of 0.1 as the cut-off) 
will be taken as evidence of poolability across the sites. Any interaction term that is statistically significant will 
trigger an examination of the data at the relevant site to determine the underlying reason(s). Since the power 
associated with testing for a significant interaction is likely to be low, the difference between the two 
treatment groups will be reported descriptively for each investigational site.  A similar approach will be used to 
assess poolability across donor types. 
 
 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430890] characteristics as well as all available 
components of EAD collected during study follow- up. Additional sensitivity analyses could include “completers 
only,” last observation carried forward, and/or mixed models.  
 
For all secondary endpoints, data will be summarized for those recipi[INVESTIGATOR_346850].  In the instances 
where data is collected only if standard of care, results will be summarized for those recipi[INVESTIGATOR_346851].  The following variables are collected only as standard of care;  
a. Serum gamma-glutamyl transferase (GGT; measured in IU/L) 
b. Daily serum lactate (measured in mmol/L) while admitted to ICU 
 
9.2 SA MPLE SIZE 
It is expected that normothermic machine perfusion will be more effective than static cold storage in terms of 
EAD. Olthoff et al.  (2010), who developed the EAD definition, showed an EAD incidence of 23%, based on data 
from 300 liver transplants from 3 US centers between 2004 and 2005 [40]. Estimates of EAD rates in DCD 
donors have been shown to be closer to 40% [44]. EAD incidence data from livers transplanted using machine 
perfusion is limited. Using hypothermic machine perfusion Guarrera et al . showed a decrease in EAD incidence 
from 25% to 5% in a prospective cohort pi[INVESTIGATOR_14737] 20 livers compared to matched controls [25] . The [LOCATION_006] 
pi[INVESTIGATOR_14737] 20 liver transplants using normothermic machine perfusion showed a decrease in EAD incidence 
from 22.5% to 15% compared to matched controls. Based on all the available data this study has been 
powered to demonstrate a reduction in EAD from 25% to 10% in NMP versus SCS. The sample size estimate is 
based on a one-sided significance level of 0.025 and power of 90%. The pooled Z-test is the test statistic, and 
the assumption of the covariate distribution is that the difference between the two proportions is zero . The 
final sample size of 266 transplanted livers (minimum of 120 in each arm), will be achieved by [CONTACT_346903] 356 transplanted livers (assumes approximately 25% attrition).   Recipi[INVESTIGATOR_346852] a 
reallocated liver but are not enrolled in the study (cases of emergency use) will not contribute to the final 
sample size of [ADDRESS_430891] recorded, and from which participants’ eCRF data are obtained.  
These include, but are not limited to, hospi[INVESTIGATOR_1097] (from which medical history and previous and 
concurrent medication may be summarized into the eCRF), clinical and office charts, laboratory reports, 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430892] diaries or logs, microfiches, radiographs, correspondence, device accountability 
records, recorded data from automated instruments, copi[INVESTIGATOR_110799], and at medico-technical departments involved in the clinical investigation. 
All documents will be stored safely in confidential conditions.  On all trial-specific documents, other than the 
signed consent, the participant will be referred to by [CONTACT_346904]/code, not by [CONTACT_2300]. 
10.1.2  DATA RECORDING  
Data collection will be achieved using an electronic data capture (EDC ) system.  Data will be input by [CONTACT_346905]/ coordinators  trained in the use of the system prior to receiving log -in details.  
All blood samples will be analyzed in local laboratories and results recorded in common units. 
 
10.2 DA TA MANAGEMENT  
10.2.1  DATA FORMS AND DATA ENTRY  
As described in section 10.1.2, data will be entered into an electronic data capture (EDC) system. Validation 
rules will ensure that data are entered in the correct format, within valid ranges and minimize the chance of 
missing data.  Data already entered will be retrievable for viewing.  The extent of an individual user’s activity in 
the database will be limited by [CONTACT_346906]/her log-in and password. 
All electronic data will be stored in a secure fashion on password protected servers, with data identified only 
by [CONTACT_346907].  Identification of study participants, if required for safety reasons, will be 
available at the study site. 
10.2.2  DISCREPANCIES AND MISSING DATA 
Visual and electronic data review will be performed to identify potential discrepancies and missing data. 
Manual and automatic queries will be created in the EDC system by [CONTACT_346908]. The Investigators/coordinators will be responsible for resolving the queries in the database. 
10.2.[ADDRESS_430893] 15 years following study close-out. 
11. QUALITY ASSURANCE , AUDIT  AND TRAINING  
11.1 MO NITORING  
The sponsor will be responsible for the local Inve stigator’s compliance with the trial protocol and for 
performing source document verification. 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430894] set aside a reasonable amount of his/her time for these visits and 
the time of the relevant site personnel. 
 
11.[ADDRESS_430895] of the study at the study site. These procedures are in accordance with Good 
Clinical Practice (GCP) to ensure that complete, accurate, and timely data are collected, that the trial protocol 
requirements are followed and that all complications and adverse events are reported in a timely manner. The 
FDA could potentially conduct audits/inspections. 
The Investigator and the relevant site personnel must set aside a reasonable amount of his/her time for study 
related monitors, audits, and inspection by [CONTACT_346909], IRB , FDA, and 
institution compliance and quality assurance groups, and provide adequate access to all study related 
documents (e.g., source documents, regulatory documents, data collection instruments, study data, etc. ). 
11.[ADDRESS_430896] undergo relevant training in advance of the site initiation in accordance with Good 
Clinical Practice (GCP) guidelines.  Such training will be documented.  
In addition, training on the investigational device will be provided in advance of recruitment of the first 
subject.  A record of all device training will be maintained.  All personnel involved in randomization and data 
entry will also be trained in the use of the online randomization and data collection tool by [CONTACT_346910], and records of such training will be maintained. 
11.4  STUDY DOCUMENTATION  
It is the responsibility of the local Investigator to maintain complete, accurate, and current study records. Each 
Investigator will be provided with an Investigator site file, access to the online case reporting system, and 
other associated study specific documentation by [CONTACT_346911]. Such records will be maintained 
during the course of the study and for a period of 2 years after the latter of the following two dates: The date 
on which the investigation is terminated or completed, or the date that the records are no longer required fo r 
purposes of supporting a premarket approval application or notice of completion of a product development 
protocol.   
12. PROTOCOL DEVIATIONS  
12.[ADDRESS_430897] this study in accordance with this protocol and any conditions o f 
approval/notification imposed by [CONTACT_1622].  Failure to comply with and/or inability to meet these regulations 
may jeopardize further participation of the Investigator or investigative site in this clinical study.   
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 48 of 57 
CONTROLLED COPY A “protocol deviation ” is a failure to adhere to the requirements specified in this study protocol.  Examples 
may include, but are not limited to, the enrollment of a study subject who does not meet all of the 
inclusion/exclusion criteria specified in section 5.3, missed study procedures, or missed study visits. 
12.[ADDRESS_430898], will be submitted 
to the investigative site’s IRB  for approval.  Before the study can begin, each Investigator must have written 
evidence of IRB approval and the sponsor must have approval from the FDA. 
Once approval has been granted, the Investigator is responsible for ensuring that he/she complies with the 
terms of the approval, namely with adverse event reporting, protocol deviation reporting, notification of 
amendments, interim, annual, and final reports on the progress of the study. 
13.[ADDRESS_430899] 
population, sample sizes, study procedures or significant administrative aspects will require a formal written 
amendment to the study protocol. 
All amendments to the protocol will be notified to the local regulatory authorities and IRBs for approval.  
Approved amendments will be circulated promptly to all Investigators by [CONTACT_346911]. 
Amendments will be tracked by [CONTACT_346912] A2 of this document. 
13.3 REPORTING  
13.3.1  SPONSOR REPORTS  
The following reports are required by [CONTACT_235147] §812.150. All reports to FDA should be identified as 
IDE Reports. 
 Unanticipated Adverse Device Effects 
The sponsor must report the results of an evaluation of an unanticipated adverse device effect to FDA and all 
reviewing IRBs and investigators within [ADDRESS_430900]. 
 Withdrawal of IRB Approval 
The sponsor must notify FDA and all reviewing IRBs and participating investigators of the withdrawal of IRB 
approval of an investigation (or any part of an investigation) within 5 working days of receipt of the withdrawal 
of approval. 
 Withdrawal of FDA Approval 
The sponsor must notify all reviewing IRBs and participating investigators of any withdrawal of FDA approval 
within 5 working days after receipt of the notice. 
 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 49 of 57 
CONTROLLED COPY  Current List of Investigators  
Every six months the sponsor must submit to FDA a current list of the names and addresses of all investigators 
participating in a significant risk device investigation. 
 Progress Reports (or Annual Reports) 
At regular intervals and at least yearly, the sponsor must provide progress reports to all reviewing IRBs. For a 
significant risk device, the sponsor must also submit the progress report to FDA.  A suggested format is 
provided below. 
 Recalls and Device Disposition 
The sponsor must notify FDA and all reviewing IRB’s of any req uest that an investigator return, repair, or 
dispose of any unit of an investigational device. The notice must be made within [ADDRESS_430901] was made. 
 Final Report 
The sponsor must notify FDA and all reviewing IRBs within [ADDRESS_430902] also submit a final report to FDA and all reviewing IRBs and participating 
investigators within 6 months after the completion or termination of the investigation. A suggested format is 
provided by [CONTACT_8415].   
 Failure to Obtain Informed Consent 
Sponsors must submit a copy of any report by [CONTACT_346913] a device without first obtaining 
informed consent. The report must be made to FDA within 5 working days after receipt of the notice of such 
use. 
 Significant Risk Device Determination 
If an IRB determines that the device is a significant risk device and not a non-significant risk device as the 
sponsor had proposed to the IRB, a report must be submitted to FDA within 5 working days after the sponsor 
learns of the IRB’s determination.  
 Other Reports   
The sponsor must provide accurate, complete, and current information about any aspect of the investigation 
upon request from the reviewing IRB or FDA. 
13.3.[ADDRESS_430903] provide the following reports to the sponsor in a timely manner under §812.150. 
 Unanticipated Adverse Device Effects 
The investigator must submit to the sponsor and the reviewing IRB a report of any unanticipated adverse 
device effect as soon as possible but no later than [ADDRESS_430904]. 
 Withdrawal of IRB Approval 
The investigator must report to the sponsor a withdrawal of approval of the reviewing IRB within 5 working 
days. 
 Progress Reports 
The investigator must submit progress reports to the sponsor and the reviewing IRB at regular intervals but no 
less than on a yearly basis. 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 50 of 57 
CONTROLLED COPY  Deviations from the Investigational Plan 
The investigator must notify the sponsor and the reviewing IRB of any deviation from the investigational plan 
to protect the life or physical well-being of a subject in an emergency. The notice must be provided as soon as 
possible but no later than [ADDRESS_430905] 
report the use to the sponsor and to the reviewing IRB within 5 working days after the use 
occurs. 
o Final Report: The investigator must submit a final report to the sponsor and to the reviewing 
IRB within 3 months after termination or completion of the investigation. 
o Other Reports: The investigator must provide accurate, complete, and current information 
about any aspect of the investigation upon request from the reviewing IRB or FDA. 
 Investigator Annual Progress Reports and Final Reports 
The IDE regulations do not specify the content of the annual progress or final reports. Therefore, the contents 
of these reports may largely be dictated by [CONTACT_456]. With respect to reports to the IRB, the IRB itself may 
specify what information it wishes to be included in these reports. Because FDA does require the information 
listed below, it is suggested that, at a minimum, the annual progress and final reports to the sponsor and the 
IRB include the following items: 
 IDE number 
 Device name 
 Indications for use 
 Brief summary of study progress in relation to investigational plan 
 Number of subjects enrolled 
 Number of devices received, used, and, in the final report, the final disposition of unused devices 
 Brief summary of results and, in the final report, conclusions 
 Summary of anticipated and unanticipated adverse device effects 
 Description of any deviations from investigational plan 
 Reprints of any articles published by [CONTACT_346914] 
  
13.4 PA RTICIPANT CONFIDENTIALITY  
All study-related information will be stored securely both at the study sites and with the trial management 
team.  Written information will be stored in locked filing cabinets in areas with limited access.  All 
documentation and specimens will be identified by a unique study ID number to maintain participant 
confidentiality.   
Participant’s information will not be released outside of the study without the written consent of the 
participant, except as necessary by [CONTACT_12721]. 
13.5  EX PENSES AND BENEFITS  
Where possible, study visits and investigations will be conducted during routine hospi[INVESTIGATOR_346853].   
 
 
WP01 Protocol: Version 10.0: 24/Jun/[ADDRESS_430906] confidence.  It 
is understood that the confidential information provided to local Investigators will not be disclosed to others 
without authorization from the sponsor and/or trial management team. 
The scientific integrity of the study requires that all data must be analyzed study-wide and reported as such.   
14.[ADDRESS_430907] presentation and 
publication, secondary publications will be delegated to the appropriate principal authors, and final analyses 
and manuscript review for all multi-center data and/or single-center experience reports will require review 
from OrganOx.
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 52 of 57 
CONTROLLED COPY APPENDIX A1: TIMELINE FOR INTERVENTIONS AND ASSESSMENTS DURING THE STUDY  
Activity  Pre-study  
Screening  Pre-study  
Baseline  Pre-
storage  Pre-
reperfusion  Post -reperfusion  Postoperative  
 D1 D2 D3 D4 D5 D6 D7 D10 D30 M3 M6 M12  
Visit Windows       12-24h 24-48h 48-72h 72-96h 96-120h  120-
144h  144-
168h  216-
240h  +/-7d +/- 
14d +/-14d +/- 30d 
Informed consent  X                 
Inclusion/  exclusion 
criteria  X                 
Randomi zation   X                
Donor & recipi[INVESTIGATOR_346854]   X                
Perfusion 
parameters/samples      X              
Lactate values      X             
Surgical variables      X             
Graft biopsy    X X X             
Serum AST       X X X X X X X  X X X  
Serum  ALT      X X X X X X X  X X X  
Serum ALP       X X X X X X X  X X X  
Total Serum Bilirubin       X X X X X X X  X X X  
Serum GGT **      X X X X X X X  X X X  
PT/INR      X X X X X X X  X X X  
Serum Albumin**       X X X X X X X  X X X  
Serum Creatinine**       X X X X X X X  X X X  
Serum lactate (*)(**)       X X X X X X X      
Medication Log             X  X X X  
Primary non -function              X     
Graft survival       X X X X X X X X X X X X 
Subject  survival       X X X X X X X X X X X X 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 53 of 57 
CONTROLLED COPY * Serum lactate will be recorded daily while the recipi[INVESTIGATOR_346855] ( ICU) care. 
** Only collected if Standard of Care Quality of life 
measure  
(EQ-5D-5L)  X              X  
Resource use               X X X X 
Safety outcomes      X X X X X X X X X X X X  
Readmissions               X X X X 
RRT Requirement       X X X X X X X X X X X X 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 54 of 57 
CONTROLLED COPY APPENDIX A2: PROTOCOL AMENDMENTS  
Version  Date  Amendments  
1.0 26/11/2014  Original Version  
2.0 10/07/2015  Amended primary endpoint and other modifications  
3.0 
4.0 
5.0        
6.0             
7.0       
8.0                     01/10/2015  
07/09/2015                
02/11/2015  
20/11/2015  
23/11/2015  
16/12/[ADDRESS_430908] page  
9.0 22/03/2016  FDA A00 3 
10.0  24/06/2016  FDA A00 4 
 
 
  
 
  
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 55 of 57 
CONTROLLED COPY REFERENCES  
1. Boyarsky, B.J., et al., Potential limitations of presumed consent legislation.  Transplantation, 2012. 93(2): p. 
136-40. 
2. Ghobrial, R.M., et al., Donor morbidity after living donation for liver transplantation.  Gastroenterology, 
2008. 135(2): p. 468- 76. 
3. Feng, S., et al., Characteristics associated with liver graft failure: the concept of a donor risk index.  Am J 
Transplant, 2006. 6(4): p. 783- 90. 
4. Blok, J.J., et al., Validation of the donor risk index in orthotopic liver transplantation within the 
Eurotransplant region.  Liver Transpl, 2012. 18(1): p. 112- 9. 
5. Merion, R.M., et al., Donation after cardiac death as a strategy to increase deceased donor liver availability.  
Ann Surg, 2006. 244(4): p. 555- 62. 
6. Waki, K., UNOS Liver Registry: ten year survivals.  Clin Transpl, 2006: p. 29- 39. 
7. Foley, D.P., et al., Biliary complications after liver transplantation from donation after cardiac death donors: 
an analysis of risk factors and long-term outcomes from a single center.  Ann Surg, 2011. 253(4): p. 817- 25. 
8. van der Hilst, C.S., et al., The price of donation after cardiac death in liver transplantation: a prospective cost-
effectiveness study.  Transpl Int, 2013. 26(4): p. 411- 8. 
9. Otero, A., et al., Liver transplantation from Maastricht category 2 non-heart-beating donors.  
Transplantation, 2003. 76(7): p. 1068-[ADDRESS_430909]: a potential solution to 
the shortage of organ donors in the [LOCATION_008]?  Transpl Int, 2011. 24(5): p. 477-81. 
11. Gagandeep, S., et al., Expanding the donor kidney pool: utility of renal allografts procured in a setting of 
uncontrolled cardiac death.  Am J Transplant, 2006. 6(7): p. 1682- 8. 
12. Muiesan, P., et al., Single-center experience with liver transplantation from controlled non-heartbeating 
donors: a viable source of grafts.  Ann Surg, 2005. 242(5): p. 732- 8. 
13. Garcia-Valdecasas, J.C., et al., Liver conditioning after cardiac arrest: the use of normothermic recirculation in 
an experimental animal model.  Transpl Int, 1998. 11(6): p. 424-32. 
14. St Peter, S.D., et al., Extended preservation of non-heart-beating donor livers with normothermic machine 
perfusion.  Br J Surg, 2002. 89(5): p. 609- 16. 
15. Furukawa, H., et al., Cold ischemia time vs outcome of human liver transplantation using UW solution.  
Transplant Proc, 1991. 23(1 Pt 2): p. 1550- 1. 
16. Adam, R., et al., Effect of extended cold ischemia with UW solution on graft function after liver 
transplantation.  Lancet, 1992. 340(8832): p. 1373- 6. 
17. Johnson, S.R., et al., Primary nonfunction (PNF) in the MELD Era: An SRTR database analysis.  Am J 
Transplant, 2007. 7(4): p. 1003- 9. 
18. Howard, T.K., et al., The influence of preservation injury on rejection in the hepatic transplant recipi[INVESTIGATOR_841].  
Transplantation, 1990. 49(1): p. 103- 7. 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 56 of 57 
CONTROLLED COPY 19. Glanemann, M., et al., Clinical implications of hepatic preservation injury after adult liver transplantation.  
Am J Transplant, 2003. 3(8): p. 1003- 9. 
20. Carrel, A. and C.A. Lindbergh, The culture of whole organs.  Science, 1935. 81(2112): p. 621- 3. 
21. Bretischneider, L., C.G. Groth, and T.E. Starzl, Chapter 22. Experimental and clinical preservation of 
orthotopic liver homografts. , in Organ Perfusion and Preservation.  1970, Appleton, Century and Crofts: New 
York. 
22. Abouna, G.M., et al., Long-term hepatic support by [CONTACT_346915]-species liver perfusions.  Lancet, 1970. 
2(7669): p. 391- 6. 
23. Jochmans, I., et al., Machine perfusion versus cold storage for the preservation of kidneys donated after 
cardiac death: a multicenter, randomized, controlled trial.  Ann Surg, 2010. 252(5): p. 756- 64. 
24. Moers, C., et al., Machine perfusion or cold storage in deceased-donor kidney transplantation.  N Engl J Med, 
2009. 360(1): p. 7- 19. 
25. Guarrera, J.V., et al., Hypothermic machine preservation in human liver transplantation: the first clinical 
series.  Am J Transplant, 2010. 10(2): p. 372- 81. 
26. Henry, S.D., et al., Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion 
injury in human liver transplantation.  Am J Transplant, 2012. 12(9): p. 2477- 86. 
27. Brockmann, J., et al., Normothermic perfusion: a new paradigm for organ preservation.  Ann Surg, 2009. 
250(1): p. 1- 6. 
28. Schon, M.R., et al., Liver transplantation after organ preservation with normothermic extracorporeal 
perfusion.  Ann Surg, 2001. 233(1): p. 114-23. 
29. Imber, C.J., et al., Advantages of normothermic perfusion over cold storage in liver preservation.  
Transplantation, 2002. 73(5): p. 701- 9. 
30. Fondevila, C., et al., Superior preservation of DCD livers with continuous normothermic perfusion.  Ann Surg, 
2011. 254(6): p. 1000- 7. 
31. Hosgood, S.A. and M.L. Nicholson, First in man renal transplantation after ex vivo normothermic perfusion.  
Transplantation, 2011. 92(7): p. 735- 8. 
32. Nicholson, M.L. and S.A. Hosgood, Renal transplantation after ex vivo normothermic perfusion: the first 
clinical study.  Am J Transplant, 2013. 13(5): p. 1246-52. 
33. Butler, A.J., et al., Successful extracorporeal porcine liver perfusion for 72 hr.  Transplantation, 2002. 73(8): p. 
1212- 8. 
34. Friend, P.J., et al., Normothermic perfusion of the isolated liver.  Transplant Proc, 2001. 33(7-8): p. 3436- 8. 
35. Imber, C.J., et al., Optimisation of bile production during normothermic preservation of porcine livers.  Am J 
Transplant, 2002. 2(7): p. 593- 9. 
36. Reddy, S.P., et al., Preservation of porcine non-heart-beating donor livers by [CONTACT_346916].  Transplantation, 2004. 77(9): p. 1328- 32. 
37. Reddy, S., et al., Non-heart-beating donor porcine livers: the adverse effect of cooling.  Liver Transpl, 2005. 
11(1): p. 35- 8. 
WP01 Protocol: Version 10.0: 24/Jun/2016  Page 57 of 57 
CONTROLLED COPY 38. Xu, H., et al., Excorporeal normothermic machine perfusion resuscitates pig DCD livers with extended warm 
ischemia.  J Surg Res, 2012. 173(2): p. e83- 8. 
39. Gaffey, M.J., et al., Predictive value of intraoperative biopsies and liver function tests for preservation injury 
in orthotopic liver transplantation.  Hepatology, 1997. 25(1): p. 184- 9. 
40. Olthoff, K.M., et al., Validation of a current definition of early allograft dysfunction in liver transplant 
recipi[INVESTIGATOR_346856].  Liver Transpl, 2010. 16(8): p. 943- 9. 
41. Chung, I.S., et al., Incidence and predictors of post-reperfusion syndrome in living donor liver transplantation.  
Clin Transplant, 2012. 26(4): p. 539-43. 
42. Hilmi, I., et al., The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in 
patients undergoing orthotopic liver transplantation.  Liver Transpl, 2008. 14(4): p. 504- 8. 
43. Abraham, S. and E.E. Furth, Quantitative evaluation of histological features in "time-zero" liver allograft 
biopsies as predictors of rejection or graft failure: receiver-operating characteristic analysis application.  Hum 
Pathol, 1996. 27(10): p. 1077- 84. 
44. Lee, D.D., et al ., Early allograft dysfunction in liver transplantation with donation after cardiac death donors 
results in inferior survival.  Liver Transplantation, 2014. 20(12) : p. 1447- 53.  
 